<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Publishing DTD v2.3 20070202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName journalpublishing.dtd?><?SourceDTD.Version 2.3?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">World J Diabetes</journal-id><journal-id journal-id-type="publisher-id">WJD</journal-id><journal-title-group><journal-title>World Journal of Diabetes</journal-title></journal-title-group><issn pub-type="epub">1948-9358</issn><publisher><publisher-name>Baishideng Publishing Group Inc</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">6347654</article-id><article-id pub-id-type="other">jWJD.v10.i1.pg1</article-id><article-id pub-id-type="doi">10.4239/wjd.v10.i1.1</article-id><article-categories><subj-group subj-group-type="heading"><subject>Review</subject></subj-group></article-categories><title-group><article-title>Update on biomarkers of glycemic control</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Krha&#x0010d;</surname><given-names>Maja</given-names></name><aff>Division of Laboratory Medicine, Department of Medical Biochemistry and Laboratory Medicine, Merkur University Hospital, Zagreb 10000, Croatia</aff></contrib><contrib contrib-type="author"><name><surname>Lovren&#x0010d;i&#x00107;</surname><given-names>Marijana Vu&#x0010d;i&#x00107;</given-names></name><aff>Division of Laboratory Medicine, Department of Medical Biochemistry and Laboratory Medicine, Merkur University Hospital, Zagreb 10000, Croatia. <email>vucic@idb.hr</email></aff></contrib></contrib-group><author-notes><fn><p>Author contributions: The authors equally contributed to this paper in the conception, literature review and analysis, drafting and editing, and final approval of the submission.</p><p>Corresponding author: Marijana Vu&#x0010d;i&#x00107; Lovren&#x0010d;i&#x00107;, PhD, Senior Scientist, Division of Laboratory Medicine, Department of Medical Biochemistry and Laboratory Medicine, Merkur University Hospital, Zaj&#x0010d;eva 19, Zagreb 10000, Croatia. <email>vucic@idb.hr</email></p><p>Telephone: +385-1-2353861 Fax: +385-1-2353847</p></fn></author-notes><pub-date pub-type="ppub"><day>15</day><month>1</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>15</day><month>1</month><year>2019</year></pub-date><volume>10</volume><issue>1</issue><fpage>1</fpage><lpage>15</lpage><history><date date-type="received"><day>29</day><month>8</month><year>2018</year></date><date date-type="rev-recd"><day>14</day><month>11</month><year>2018</year></date><date date-type="accepted"><day>5</day><month>12</month><year>2018</year></date></history><permissions><copyright-statement>&#x000a9;The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.</copyright-statement><copyright-year>2019</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p>This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.</license-p></license></permissions><abstract><p>Attaining and maintaining good glycemic control is a cornerstone of diabetes care. The monitoring of glycemic control is currently based on the self-monitoring of blood glucose (SMBG) and laboratory testing for hemoglobin A1c (HbA1c), which is a surrogate biochemical marker of the average glycemia level over the previous 2-3 mo period. Although hyperglycemia is a key biochemical feature of diabetes, both the level of and exposure to high glucose, as well as glycemic variability, contribute to the pathogenesis of diabetic complications and follow different patterns in type 1 and type 2 diabetes. HbA1c provides a valuable, standardized and evidence-based parameter that is relevant for clinical decision making, but several biological and analytical confounders limit its accuracy in reflecting true glycemia. It has become apparent in recent years that other glycated proteins such as fructosamine, glycated albumin, and the nutritional monosaccharide 1,5-anhydroglucitol, as well as integrated measures from direct glucose testing by an SMBG/continuous glucose monitoring system, may provide valuable complementary data, particularly in circumstances when HbA1c results may be unreliable or are insufficient to assess the risk of adverse outcomes. Long-term associations of these alternative biomarkers of glycemia with the risk of complications need to be investigated in order to provide clinically relevant cut-off values and to validate their utility in diverse populations of diabetes patients.</p></abstract><kwd-group><kwd>Diabetes mellitus</kwd><kwd>Hemoglobin A1c</kwd><kwd>Fructosamine</kwd><kwd>Glycated albumin</kwd><kwd>1,5-anhydroglucitol</kwd><kwd>Plasma glucose</kwd><kwd>Glucose variability</kwd><kwd>Diabetic complications</kwd></kwd-group></article-meta></front><body><p><bold>Core tip:</bold> Monitoring of glycemic control is currently based on the self-monitoring of blood glucose and laboratory testing for hemoglobin A1c (HbA1c), which is a surrogate marker of the average glycemia level over the past 2-3 mo. The severity of hyperglycemia and glycemic variability contribute to the pathogenesis of complications, but the HbA1c measurement reflects only a piece of these important variables. In this review, we provide a critical update on the use of HbA1c and alternative biomarkers of glycemic control, with particular emphasis on the need for a personalized approach in utilizing and interpreting different tests in a clinically meaningful manner.</p><sec><title>INTRODUCTION</title><p>Attaining and maintaining good glycemic control is the cornerstone of diabetes care[<xref rid="B1" ref-type="bibr">1</xref>]. The results of the seminal Diabetes Control and Complications Trial (DCCT) clearly evidenced that glycemic control is causatively related to microvascular complications in type 1 diabetes[<xref rid="B2" ref-type="bibr">2</xref>]. A long-term follow-up in the Epidemiology of Diabetes Interventions and Complications Study (EDIC) confirmed that keeping glycemia as close as possible to its normal range with intensified insulin therapy ameliorated both microvascular and cardiovascular complications for 30 years in the same cohort of patients[<xref rid="B3" ref-type="bibr">3</xref>].</p><p>Similar evidence of the beneficial effect of intensive glucose control practices in reducing the risk of diabetic complications, adverse cardiovascular outcomes and mortality were shown in type 2 diabetes patients in both the United Kingdom Prospective Diabetes Study (UKPDS) intervention and in follow-up trials[<xref rid="B4" ref-type="bibr">4</xref>,<xref rid="B5" ref-type="bibr">5</xref>]. However, although additional intensification of glucose control in type 2 diabetes patients provided some benefits[<xref rid="B6" ref-type="bibr">6</xref>,<xref rid="B7" ref-type="bibr">7</xref>], it was associated with serious adverse outcomes such as an increased overall mortality[<xref rid="B8" ref-type="bibr">8</xref>] that was most likely due to severe hypoglycemia as a side-effect of a more aggressive antihyperglycemic therapy[<xref rid="B9" ref-type="bibr">9</xref>]. These data indicated that a personalized approach to glycemic goals that uses clinically validated biomarkers rather than a &#x0201c;one-size-fits-all&#x0201d; concept may provide a valid rationale for optimal diabetes care.</p><p>The concept of glycemic control monitoring is currently based on self-monitoring of blood glucose (SMBG) and laboratory testing for hemoglobin A1c (HbA1c), which is a surrogate biochemical marker of the average glycemia level over the previous 2-3 mo period[<xref rid="B10" ref-type="bibr">10</xref>]. HbA1c emerged as a key determinant of the risk cut-off for diabetic complications and as a setting point for optimal glycemic control in both DCCT and UKPDS trials, and it is considered to be a gold standard of diabetes care in contemporary clinical practice[<xref rid="B11" ref-type="bibr">11</xref>]. HbA1c provides valuable, standardized and evidence-based information that is relevant for clinical decision-making; however, several biological and analytical interferences, as well as clinical conditions, limit its accuracy in reflecting the true glycemia level[<xref rid="B12" ref-type="bibr">12</xref>,<xref rid="B13" ref-type="bibr">13</xref>]. Recent technological advances in the field of continuous glucose monitoring systems (CGMS) have revealed new insights in short-term glucose dynamics which are not reflected by HbA1c, although it seems to be relevant in assessing the risk of diabetic complications[<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B15" ref-type="bibr">15</xref>].</p><p>Thus, alternative glycemic markers that provide reliable information about glycemic control in addition to and beyond HbA1c are needed to improve the quality of clinical care across a heterogeneous diabetes population[<xref rid="B16" ref-type="bibr">16</xref>,<xref rid="B17" ref-type="bibr">17</xref>].</p><p>The aim of this narrative review is to provide a critical update on the use of HbA1c and alternative biomarkers of glycemic control, with a particular emphasis given to the need for a personalized approach in utilizing and interpreting different tests in a clinically meaningful manner.</p></sec><sec><title>HBA1C</title><p>HbA1c results from the posttranslational modification of hemoglobin A by the nonenzymatic covalent binding of glucose to the N-terminal valine of the &#x003b2;-globin chain[<xref rid="B10" ref-type="bibr">10</xref>]. This reaction is termed glycation and affects all structural and circulating proteins with free amino-acid residues that are available for binding monosaccharides. The glycation of hemoglobin is a two-step chemical reaction whereby glucose covalently binds to the free amino-groups within globin chains[<xref rid="B18" ref-type="bibr">18</xref>]. The first step of this process results in labile aldimine (a Schiff base), which can either dissociate or further convert to a stabile ketoamine by an Amadori rearrangement, depending on the glucose concentration in the blood[<xref rid="B10" ref-type="bibr">10</xref>]. HbA1c was first observed as a minor chromatographic fraction of adult hemoglobin in 1958 and was named according to its chromatographic column elution sequence[<xref rid="B19" ref-type="bibr">19</xref>], but its relevance in diabetes was revealed in 1969 by Rahbar[<xref rid="B20" ref-type="bibr">20</xref>], who observed significantly higher HbA1c values in diabetic patients. Since glycation is a nonenzymatic reaction, it complies with the law of mass action. Thus, assuming normal erythropoiesis and a stable hemoglobin concentration, HbA1c reflects the average glycemia level during one red blood cell life cycle (2-3 mo)[<xref rid="B21" ref-type="bibr">21</xref>].</p><p>Considering the high biological variability, the dynamics of glucose, as well as the limitations of blood glucose monitoring technology, at that time, the possibility of obtaining an integrated average glycemia value by the measurement of a single biomarker elicited immense interest and provided a powerful tool in both diabetes research and clinical management. HbA1c testing was soon facilitated by the development of a new analytical methodology that was suitable for use in clinical laboratories.</p><p>Various analytical methods for HbA1c determination commonly utilize either of the two principles (Table <xref rid="T1" ref-type="table">1</xref>): (1) HbA1c separation from other hemoglobin fractions that is based on charge differences using either chromatography or electrophoresis; or (2) the direct measurement of HbA1c by specific binding (immunochemistry or affinity) or enzymatic cleavage[<xref rid="B22" ref-type="bibr">22</xref>]. Due to differences between these analytical methods in their use of different principles and a lack of standardization, HbA1c testing inherently suffers from a significant between-method variability which has seriously affected its clinical accuracy in the longitudinal monitoring of average glycemia with different methods and comparing the results of the DCCT- and UKPDS-derived targets. Heterogeneity of molecular entities that were measured by different methods significantly contributed to the analytical variability, as the glycation reaction involved not only &#x003b2;-N-terminal valine but also other accessible amino groups within the &#x003b1; and &#x003b2;-globin chains, and these results depended on the type of analyte that was captured by a particular method[<xref rid="B12" ref-type="bibr">12</xref>]. Thus, the standardization of the HbA1c measurement and reporting that included a uniform definition of the analyte was shortly identified as one of the most important issues in diabetes care[<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B24" ref-type="bibr">24</xref>].</p><table-wrap id="T1" position="float"><label>Table 1</label><caption><p>Characteristics of the analytical methods for hemoglobin A1c measurement</p></caption><table frame="hsides" rules="groups"><thead align="center"><tr><td align="left" rowspan="1" colspan="1"><bold>Method</bold></td><td rowspan="1" colspan="1"><bold>Advantages</bold></td><td rowspan="1" colspan="1"><bold>Disadvantages</bold></td></tr></thead><tbody align="center"><tr><td align="left" rowspan="1" colspan="1">Ion exchange chromatography</td><td rowspan="1" colspan="1">DCCT method, high reproducibility</td><td rowspan="1" colspan="1">Lack of specificity; interference from hemoglobinopathies and HbF</td></tr><tr><td align="left" rowspan="1" colspan="1">Capillary electrophoresis</td><td rowspan="1" colspan="1">High reproducibility; specificity</td><td rowspan="1" colspan="1">Time-consuming, costly</td></tr><tr><td align="left" rowspan="1" colspan="1">Boronate affinity chromatography</td><td rowspan="1" colspan="1">Minimal interference from hemoglobinopathies</td><td rowspan="1" colspan="1">Analyte-related unspecificity (total GHb)</td></tr><tr><td align="left" rowspan="1" colspan="1">Immunoassay</td><td rowspan="1" colspan="1">Specificity</td><td rowspan="1" colspan="1">Some interference from HbF</td></tr></tbody></table><table-wrap-foot><fn><p>DCCT: Diabetes Control and Complications Trial; HbF: Fetal hemoglobin; GHb: Total glycated hemoglobin.</p></fn></table-wrap-foot></table-wrap><p>Clinical harmonization was accomplished within the National Glycohemoglobin Standardization Program (NGSP), which was established by the American Diabetes Association (ADA) and the American Association of Clinical Chemistry (AACC). The goal of the NGSP was to harmonize the HbA1c results that were obtained by different methods with the highly reproducible but insufficiently specific method (ion-exchange chromatography) that was used in the DCCT and UKPDS trials, thereby enabling the traceability and comparability of results to the evidence-based clinical criteria[<xref rid="B25" ref-type="bibr">25</xref>]. Almost simultaneously to the NGSP, the International Federation of Clinical Chemistry (IFCC) set up an HbA1c Standardization Program that was aimed at designing a comprehensive reference system with both reference methods and a primary reference standard for a structurally-defined analyte[<xref rid="B23" ref-type="bibr">23</xref>,<xref rid="B26" ref-type="bibr">26</xref>,<xref rid="B27" ref-type="bibr">27</xref>]. The comparison between the two reference systems revealed an excellent linear correlation between the DCCT- and IFCC-reference systems but significantly lower HbA1c values with the latter, more specific method. This finding raised concerns regarding the risks of deterioration of the glycemic control with the adoption of the new reference system, which had been reported previously[<xref rid="B28" ref-type="bibr">28</xref>].</p><p>In 2010, a Global Consensus on HbA1c measurement and reporting was issued by an international committee representing the ADA, European Association for the Study of Diabetes (EASD), International Diabetes Federation (IDF), IFCC and International Society for the Pediatric Diabetes (ISPAD)[<xref rid="B29" ref-type="bibr">29</xref>]. Briefly, the Global Consensus defined the IFCC reference as the only valid anchor for commercial methods calibration and a dual reporting of the HbA1c results as mmol/mol (IFCC-related units) and % (NGSP/DCCT-related units). A master equation describing the relationship between the two reference systems should be used for the interconversion of the results:</p><p>HbA1c NGSP/DCCT (%) = 0.09148 &#x000d7; HbA1c IFCC (mmol/mol) + 2.152</p><p>HbA1c IFCC (mmol/mol) = 10.93 &#x000d7; HbA1c NGSP/DCCT (%) - 23.50</p><p>Editors of scientific journals were encouraged to require both units of HbA1c reporting to promote the clarity and comparability of results between studies that used HbA1c as an outcome measure and to facilitate the combination of these results in meta-analyses. The Global Consensus definitely enabled the uniform traceability and improved analytical quality of HbA1c measurements[<xref rid="B12" ref-type="bibr">12</xref>]; however, it failed to harmonize the reporting of these results, as different countries use different reporting units, which may thus complicate a direct comparison of results across the world[<xref rid="B30" ref-type="bibr">30</xref>].</p><p>Today, the analytical procedures for HbA1c measurement are harmonized and the between-method/laboratory variabilities have been gradually reduced towards a desirable goal, which is a coefficient of variation (CV) &#x0003c; 3.5%[<xref rid="B12" ref-type="bibr">12</xref>]. Regarding the within-laboratory imprecision, current guidelines recommend a CV &#x0003c; 2% for NGSP-HbA1c equivalents[<xref rid="B31" ref-type="bibr">31</xref>], and this is achievable with almost all of the commercially available laboratory methods apart from point-of-care systems for HbA1c testing, which still need improvement[<xref rid="B22" ref-type="bibr">22</xref>]. However, global harmonization and ongoing efforts to improve the analytical quality[<xref rid="B32" ref-type="bibr">32</xref>] cannot obviate the limitations of HbA1c measurement due to the hemoglobin-related interferences.</p><p>It has long been recognized that hemoglobin variants interfere with HbA1c synthesis and measurement, and this interference depends on the nature of the congenital disorder afflicting hemoglobin synthesis and the analytical method that is used to measure HbA1c[<xref rid="B22" ref-type="bibr">22</xref>]. Thalassemia traits, HbS, HbC, HbE and HbF are among the most abundant hemoglobin-related interferences[<xref rid="B33" ref-type="bibr">33</xref>]. Additionally, other posttranslational modifications of hemoglobin such as carbamylation by uremic toxins in end-stage renal disease may significantly interfere with some HbA1c assays[<xref rid="B34" ref-type="bibr">34</xref>]. It should be noted that the majority of interferences have been mitigated by improvements of analytical methodologies, and the remaining interferences have been depicted and rigorously scrutinized. A comprehensive list of HbA1c methods that have been characterized for their susceptibility to hemoglobin-related interferences is available and is continuously updated on the NGSP website[<xref rid="B35" ref-type="bibr">35</xref>].</p><p>Biological confounders influencing the accuracy of HbA1c as a glycemic marker have emerged as a significant issue after analytical harmonization, despite the fact that a substantial intraindividual variability in HbA1c values was recognized long ago. Studies on the relationship between HbA1c measurements and average glycemia levels revealed a strong linear correlation with a wide interindividual variability, <italic>e.g</italic>., an HbA1c of 7% (53 mmol/mol) could correspond to an average glucose concentration ranging from 6.8 to 10.3 mmol/L[<xref rid="B36" ref-type="bibr">36</xref>]. Physiological factors such age and ethnicity, as well as genetics, seem to be major determinants of this variability.</p><p>Age was found to be associated with a gradual increase of HbA1c levels in nondiabetic individuals independently of sex and level of glycemia, indicating that age-specific reference intervals/clinical cut-off points may improve the clinical accuracy of this test in both the diagnosis and management of diabetes[<xref rid="B37" ref-type="bibr">37</xref>]. There are ethnic differences in HbA1c values even when glycemia levels are the same; a recent meta-analysis revealed that Caucasians have slightly lower HbA1c values in comparison to persons of other ethnic groups[<xref rid="B38" ref-type="bibr">38</xref>]. While the clinical relevance of this finding needs to be further investigated, the authors concluded that a better understanding of the molecular mechanisms behind this observed between-race variability in HbA1c may improve its clinical applicability.</p><p>Recent genetic studies have revealed that multiple genomic loci are associated with HbA1c levels, and this could provide a plausible explanation for the physiological factors determining its variability and clinical utilization towards a more personalized approach[<xref rid="B39" ref-type="bibr">39</xref>]. Among the 60 genetic variants that were found to influence HbA1c, 19 variants associated with glycemic pathways were identified, and among the rest of variants that were involved in nonglycemic pathways, 22 erythrocytic variants were found[<xref rid="B40" ref-type="bibr">40</xref>]. Among these, a variant on the X chromosome coding for glucose-6-phosphate dehydrogenase (G6PD) was associated with a significantly higher HbA1c variability in populations of African ancestry when compared to other ethnic groups. This highly prevalent variant is associated with a shorter erythrocyte lifespan and, consequently, falsely decreased HbA1c levels, which may have serious impacts for diabetes care in afflicted individuals[<xref rid="B40" ref-type="bibr">40</xref>].</p><p>Nonglycemic factors affecting HbA1c levels include erythropoiesis, hemoglobin synthesis and conditions influencing red blood cell survival. Deficiency anemias generally elicit falsely increased HbA1c levels due to the increased levels of aged erythrocytes that are found in patients with this disease, whereas falsely decreased HbA1c levels can be observed in hemolytic anemias of any cause[<xref rid="B41" ref-type="bibr">41</xref>]. Nonhematological conditions influencing HbA1c values include pregnancy, chronic renal failure and certain medications[<xref rid="B22" ref-type="bibr">22</xref>]. Variability in the normal erythrocyte lifespan is another significant confounder of HbA1c accuracy. Malka et al[<xref rid="B42" ref-type="bibr">42</xref>] recently proposed a mechanistic mathematical model integrating hemoglobin glycation and red blood cell kinetics that provided a personalized insight into average glucose levels and reduced the occurrence of diagnostic errors due to a misinterpretation of average glycemia (as reflected by HbA1c) by more than 50%. The applicability and clinical utility of the proposed model have yet to be determined.</p><p>Furthermore, part of the variability in HbA1c is considered to be a consequence of differences in glycation rate, which is a concept that was proposed as the &#x0201c;glycation gap&#x0201d; 15 years ago[<xref rid="B43" ref-type="bibr">43</xref>]. The glycation gap hypothesis is based on the differences between the intra- and extracellular surrogate markers of average glycemia, <italic>i.e</italic>., HbA1c and fructosamine, and it was proposed as an explanation to the commonly encountered clinical problem of discrepancy between various glycemia measures that cannot be attributed to any other confounding factor[<xref rid="B44" ref-type="bibr">44</xref>]. In spite of subsequent evidence from a twin study that shows that the glycation gap may be a genetically determined characteristic of an individual[<xref rid="B45" ref-type="bibr">45</xref>], this concept has been considered implausible by some authors due to the lack of validating data or supporting evidence of the underlying mechanism[<xref rid="B46" ref-type="bibr">46</xref>]. Nevertheless, an accumulating body of evidence indicates that glycemic variability, as assessed by either the glycation gap or another discordance measure called the hemoglobin glycation index[<xref rid="B47" ref-type="bibr">47</xref>], is indeed associated with adverse diabetes-related outcomes such as mortality, micro- and macrovascular complications, and hypoglycemic episodes that are associated with intensive treatment[<xref rid="B48" ref-type="bibr">48</xref>,<xref rid="B49" ref-type="bibr">49</xref>]. Interindividual heterogeneity in glucose transport across the erythrocyte membrane was proposed as a possible explanation for inconsistencies between HbA1c and other measures of glycemia[<xref rid="B50" ref-type="bibr">50</xref>]. Genome-wide association studies also support the plausibility of the glycation gap concept since one of the identified loci, FN3K, encodes fructosamine-3-kinase, which is an enzyme that is involved in deglycation of glycated proteins[<xref rid="B39" ref-type="bibr">39</xref>]. Dunmore et al[<xref rid="B51" ref-type="bibr">51</xref>] recently reported a significant difference in the erythrocyte fructosamine-3-kinase activities between glycation gap categories and pinpointed FN3K both as a novel predictor of the risk for development of and as a potential target for the prevention of diabetic complications.</p><p>Current clinical guidelines recommend regular HbA1c testing twice a year in all diabetic patients who achieve their glycemic targets, and they recommend an increased frequency of testing not to exceed four times a year for patients who have changed therapy and/or have not achieved their treatment goals[<xref rid="B1" ref-type="bibr">1</xref>]. The general recommendation is to keep the HbA1c levels &#x0003c; 7% (53 mmol/mol); however, the target should be individualized for individual patients depending on the diabetes duration, age or life expectancy, CVD and other comorbidities, hypoglycemia unawareness and psychosocial factors[<xref rid="B52" ref-type="bibr">52</xref>]. A reference change value of 0.5% (5 mmol/mol) in the longitudinal monitoring of an individual patient is considered to be clinically significant[<xref rid="B22" ref-type="bibr">22</xref>].</p><p>The use of HbA1c as a diagnostic test for diabetes with a diagnostic cutoff set at an HbA1c level of 6.5% (48 mmol/mol) has recently been recommended by prominent professional organizations and by the Word Health Organization[<xref rid="B53" ref-type="bibr">53</xref>,<xref rid="B54" ref-type="bibr">54</xref>]. Low intraindividual biological variability, the stability of the analyte and the independence of results to the prandial status were the most pronounced advantages of HbA1c over plasma glucose, while higher costs and the limited availability of the test were considered as its disadvantages[<xref rid="B55" ref-type="bibr">55</xref>]. However, the diagnostic accuracy of HbA1c at a given threshold was found to be poor in many studies[<xref rid="B56" ref-type="bibr">56</xref>-<xref rid="B58" ref-type="bibr">58</xref>], as well as in a recent global surveillance on the prevalence and diagnosis of diabetes[<xref rid="B59" ref-type="bibr">59</xref>], which is at least in part a consequence of numerous biological confounders[<xref rid="B38" ref-type="bibr">38</xref>,<xref rid="B60" ref-type="bibr">60</xref>]. A comprehensive list of biological, (patho) physiological and pharmacological factors that may influence the synthesis, measurement and/or interpretation of HbA1c is presented in Table <xref rid="T2" ref-type="table">2</xref>.</p><table-wrap id="T2" position="float"><label>Table 2</label><caption><p>Biological, (patho)physiological and pharmacological factors influencing hemoglobin A1c</p></caption><table frame="hsides" rules="groups"><thead align="center"><tr><td align="left" rowspan="1" colspan="1"><bold>Factor influencing HbA1c synthesis/measurement/interpretation</bold></td></tr></thead><tbody align="center"><tr><td align="left" rowspan="1" colspan="1">Age, ethnicity</td></tr><tr><td align="left" rowspan="1" colspan="1">Genetic factors (e.g. Glucose-6-phosphate dehydrogenase variants)</td></tr><tr><td align="left" rowspan="1" colspan="1">Pregnancy</td></tr><tr><td align="left" rowspan="1" colspan="1">Red blood cell lifespan</td></tr><tr><td align="left" rowspan="1" colspan="1">Haemolytic anaemia</td></tr><tr><td align="left" rowspan="1" colspan="1">Iron deficiency anaemia</td></tr><tr><td align="left" rowspan="1" colspan="1">Haemoglobin variants</td></tr><tr><td align="left" rowspan="1" colspan="1">Accute haemorrhage</td></tr><tr><td align="left" rowspan="1" colspan="1">Splenomegaly</td></tr><tr><td align="left" rowspan="1" colspan="1">Splenectomy</td></tr><tr><td align="left" rowspan="1" colspan="1">Transfusion</td></tr><tr><td align="left" rowspan="1" colspan="1">Chronic liver disease</td></tr><tr><td align="left" rowspan="1" colspan="1">End-stage renal disease</td></tr><tr><td align="left" rowspan="1" colspan="1">Rheumatoid arthritis</td></tr><tr><td align="left" rowspan="1" colspan="1">Vitamin C</td></tr><tr><td align="left" rowspan="1" colspan="1">Drugs (aspirin, erytropoietin, dapsone, antiretroviral agents)</td></tr><tr><td align="left" rowspan="1" colspan="1">Endogenous interferents (high levels of bilirubin/triglycerides)</td></tr></tbody></table><table-wrap-foot><fn><p>HbA1c: Hemoglobin A1c.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>GLYCATED PROTEINS</title><p>Fructosamine (1-amino-1-deoxy fructose) is a common term for all glycated plasma proteins. It is a ketoamine that is formed by the irreversible nonenzymatic binding of glucose to plasma proteins in a process called glycation. Glycation is a nonenzymatic process where a labile Schiff base (aldimine) is formed at an early stage and is subsequently rearranged to a stabile Amadori product (ketoamine) due to the covalent binding of glucose to the lysine, arginine and cysteine amino-group residues within protein molecules[<xref rid="B61" ref-type="bibr">61</xref>].</p><p>Glycated albumin (GA) is formed in a similar reaction as fructosamine and is specific to albumin molecule[<xref rid="B62" ref-type="bibr">62</xref>]. In conditions that are associated with high glucose levels, plasma proteins are exposed to greater glycation, which leads to increased fructosamine and GA formation. Fructosamine and GA reflect the average blood glucose concentration during the lifetime of either total plasma proteins or albumin, both of which are within the range of two to three weeks[<xref rid="B63" ref-type="bibr">63</xref>].</p><p>Despite the fact that albumin is a major constituent of plasma proteins, fructosamine and GA may not be considered as totally equal measures of glycemia due to their differences in analytical procedures and their currently established clinical performance. Fructosamine was identified long ago, but the lack of analytical standardization and problems with the assay&#x02019;s specificity and susceptibility to interference by hyperlipidemia limited its use in diabetes management. Additionally, there was insufficient evidence to correlate fructosamine and GA with long-term outcomes in patients with diabetes[<xref rid="B64" ref-type="bibr">64</xref>].</p><p>However, over the years, the development and improvement of methods for determining fructosamine and GA have paved the way for many studies that focused on their analytical and clinical significance. Affinity chromatography[<xref rid="B65" ref-type="bibr">65</xref>], ion-exchange chromatography[<xref rid="B66" ref-type="bibr">66</xref>] and high-performance liquid affinity chromatography[<xref rid="B67" ref-type="bibr">67</xref>] were all developed as methods for the direct measurement of GA along with liquid chromatography-tandem mass spectrometry (LC-MS/MS) as a &#x0201c;gold standard&#x0201d;[<xref rid="B68" ref-type="bibr">68</xref>]. However, these methods are complicated and expensive and require dedicated equipment and expertise, and this has limited their routine use. Consequently, simpler and more affordable colorimetric and enzymatic methods, applicable on various automated analytical platforms, were developed for use in clinical laboratories[<xref rid="B69" ref-type="bibr">69</xref>]. Enzymatic methods showed a better analytical performance and were free of colorimetric interferences (<italic>e.g</italic>., bilirubin)[<xref rid="B70" ref-type="bibr">70</xref>-<xref rid="B72" ref-type="bibr">72</xref>]. Various commercial kits are available for GA measurement depending on the type of enzyme that was used in the reaction and the units used to express the results (&#x000b5;mol/L, mmol/L or % GA fraction).</p><p>Currently, the method of choice for fructosamine determination is the second generation of the nitroblue tetrazolium colorimetric procedure, in which there is a separation of glycated from nonglycated proteins based on their differences in chemical reactivity [<xref rid="B73" ref-type="bibr">73</xref>]. The assay itself is inexpensive, rapid, simple, highly specific and free of interferences from uric acid or polylysine. Nevertheless, despite many improvements, this method is still sensitive to rapid changes in ambient temperature and interferences from extremely high levels of some compounds with reducing properties, such as bilirubin and vitamin C[<xref rid="B64" ref-type="bibr">64</xref>]. Still unresolved is the issue of whether the resulting fructosamine measurements should be corrected for either total protein or albumin concentrations. The results are relatively ambiguous[<xref rid="B74" ref-type="bibr">74</xref>], but it was recently reported that correcting the fructosamine measurement for proteins may improve its correlation with HbA1c and its overall performance in detecting diabetes[<xref rid="B75" ref-type="bibr">75</xref>].</p><p>Given the faster protein metabolic turnover, fructosamine and GA values reflect shorter-term glycemia levels rather than HbA1c. Additionally, fructosamine and GA are not influenced by anemia or hemoglobinopathies such as HbA1c is, and they can therefore be used in conditions where HbA1c is not reliable due to analytical or biological interferences[<xref rid="B62" ref-type="bibr">62</xref>]. In conditions such as pregnancy[<xref rid="B76" ref-type="bibr">76</xref>] and treatment modifications[<xref rid="B77" ref-type="bibr">77</xref>] fructosamine and GA can detect changes in average blood glucose earlier than HbA1c and thus provide more timely information about the achievement of glycemic control[<xref rid="B62" ref-type="bibr">62</xref>,<xref rid="B78" ref-type="bibr">78</xref>,<xref rid="B79" ref-type="bibr">79</xref>].</p><p>Both fructosamine and GA are the markers of choice when glycemic control needs to be assessed in patients with severe chronic kidney disease (CKD) (stages 4 and 5)[<xref rid="B80" ref-type="bibr">80</xref>]. Additionally, in stage 5 CKD patients on hemodialysis, GA can be used as a predictor of overall survival and cardiovascular mortality[<xref rid="B81" ref-type="bibr">81</xref>]. Due to the reduced production and lifespan of red blood cells and to erythropoietin treatment in CKD patients, HbA1c cannot be used as reliable marker, as it can significantly underestimate the true glycemic status in these patients[<xref rid="B82" ref-type="bibr">82</xref>].</p><p>The distribution of GA in healthy subjects has been described in diverse populations[<xref rid="B83" ref-type="bibr">83</xref>,<xref rid="B84" ref-type="bibr">84</xref>]. The Large Atherosclerosis Risk in Communities (ARIC) study was conducted in a cohort of almost 12000 participants and proved a strong association of fructosamine and GA with the incidence of diabetes and microvascular complications (prevalent retinopathy and risk of CKD)[<xref rid="B85" ref-type="bibr">85</xref>]. Together with fructosamine, GA was reported to be strongly associated with HbA1c and fasting glucose[<xref rid="B86" ref-type="bibr">86</xref>]. Furthermore, a recent study by Bellia et al[<xref rid="B87" ref-type="bibr">87</xref>] evaluated the potential clinical usefulness of GA for the diagnosis of diabetes in an asymptomatic Caucasian population (specifically in Europe) with an elevated risk of developing diabetes. At the GA cut-off of 13.5%, a high sensitivity (88.9%; 95%CI: 65.3-98.6) and a good specificity (60.4%; 95%CI: 54.8-65.9), was demonstrated for its possible screening use in similar subjects[<xref rid="B87" ref-type="bibr">87</xref>].</p><p>It is important to note that fructosamine and GA measurements are not reliable in some physiological and pathological conditions. Every clinical condition that can affect protein and albumin metabolism (nephrotic syndrome, hyperthyroidism, glucocorticoid therapy, liver cirrhosis, <italic>etc</italic>.) may affect these results, where they would also require careful interpretation[<xref rid="B14" ref-type="bibr">14</xref>,<xref rid="B62" ref-type="bibr">62</xref>]. Additionally, similar to HbA1c, fructosamine and GA are determined by genetic variants that are associated with both glycemic and nonglycemic components, both of which should be considered when putting the results in a clinical context[<xref rid="B84" ref-type="bibr">84</xref>].</p></sec><sec><title>1,5-ANHYDROGLUCITOL</title><p>1,5-Anhydroglucitol (1,5-AG) is a monosaccharide that is structurally identical to D-glucose with the absence of the C-1 hydroxyl group. It is derived mainly through food intake and also absorbed by the intestine at a rate of approximately 4.4 mg/d. The main source of 1,5-AG is soy beans, but small amounts can be found in rice, pasta, fish, fruits, vegetables, tea, milk and cheese. The metabolic role of 1,5-AG is still quite unknown. It circulates in body in its free form and can be found in all organs and tissues (1,5-AG pool) with the total amount several times higher than that in plasma[<xref rid="B88" ref-type="bibr">88</xref>]. A negligible amount is presumed to be synthesized <italic>de novo</italic>[<xref rid="B89" ref-type="bibr">89</xref>]. 1,5-AG intake is regulated by its urinary excretion, and 99.9% of 1,5-AG is reabsorbed by the kidneys by the specific sodium glucose active cotransporter (SGLT4)[<xref rid="B88" ref-type="bibr">88</xref>,<xref rid="B90" ref-type="bibr">90</xref>]. Reabsorption is competitively inhibited by glucose. When the plasma glucose level exceeds the renal threshold for glucosuria (approximately 10 mmol/L), 1,5-AG is excreted in the urine, which results in a rapid reduction of its serum levels[<xref rid="B91" ref-type="bibr">91</xref>]. Thus, low values of 1,5-AG reflect both high circulating glucose levels and glucose fluctuation, or so-called hyperglycemic excursion[<xref rid="B92" ref-type="bibr">92</xref>]. This biomarker may be useful to differentiate between diabetic patients with well-controlled HbA1c but with extensive glucose fluctuations[<xref rid="B93" ref-type="bibr">93</xref>]. After normoglycemia is restored, the 1,5-AG concentration returns to its normal value at a rate of 0.3 &#x000b5;g/ml per day, and it can take up to 5 wk for this value to increase up to its normal level[<xref rid="B94" ref-type="bibr">94</xref>]. Due to its half-life of approximately 1 to 2 wk, 1,5-AG can be used as a potential marker for short-term glycemia[<xref rid="B95" ref-type="bibr">95</xref>]. Additionally, there is evidence that 1,5-AG reflects the 2-h postprandial glucose (PPG) values of the 2 preceding weeks in moderately controlled patients and is more sensitive and specific than HbA1c[<xref rid="B96" ref-type="bibr">96</xref>]. PPG values are especially important for clinical decision-making concerning changes in the diet or in changes of the pharmacologic treatment of diabetes and overall glycemic control[<xref rid="B97" ref-type="bibr">97</xref>].</p><p>1,5-AG can be measured in serum, EDTA-plasma and urine samples. There are two commercially available enzymatic kits for its blood measurement: the Glyco-MarkTM (GlycoMark, Inc) kit that is used in United States and the Determiner-L (Kyowa Medex, Tokyo) kit that is used in Japan. Both of these methods can be applied to automated chemistry analyzers. Recent data has shown a good between-method comparability despite slightly different results that were obtained in the same samples[<xref rid="B98" ref-type="bibr">98</xref>]. Another method for the determination of 1,5-AG is chromatography, specifically gas chromatography-mass spectrometry (GC/MS) and high-performance liquid chromatography (HPLC). These methods are sensitive and precise but require sample preparation and are time-consuming and cumbersome[<xref rid="B99" ref-type="bibr">99</xref>]. Urine, a sample with lower 1,5-AG levels, requires a more sensitive method such as liquid chromatography/mass spectrometry (LC/MS) or HPLC[<xref rid="B100" ref-type="bibr">100</xref>].</p><p>Regarding its association with diabetes and microvascular complications, the ARIC study provided evidence that 1,5-AG levels were associated with prevalent retinopathy and incident CKD, particularly in patients who were diagnosed with diabetes. Despite the low association in nondiabetic subjects, there was a good risk prediction of incident diabetes in both groups[<xref rid="B86" ref-type="bibr">86</xref>,<xref rid="B101" ref-type="bibr">101</xref>].</p><p>The results obtained from patients with certain conditions such as kidney disease or pregnancy must be carefully interpreted due to the changes in renal function during these conditions which influences the threshold for glucose excretion. Nevertheless, 1,5-AG can be reliable in subjects with mild to moderate renal insufficiency as a marker for glycemic control[<xref rid="B102" ref-type="bibr">102</xref>]. Furthermore, 1,5-AG can be helpful in cases when frequent adjustments in therapy are required and glycemic control has to be maintained[<xref rid="B94" ref-type="bibr">94</xref>].</p><p>Given the limitations of HbA1c and the recently collected evidence on the clinical utility of nontraditional markers of glycemia, their implementation in clinical practice is expected. The recently published reference intervals provide the most valuable tool in facilitating the translation of these biomarkers into routine clinical practice. In a healthy reference population of almost 1800 individuals, the reference ranges for fructosamine, GA and 1,5-AG were reported as 194.8-258.0 &#x000b5;mol/L, 10.7%-15.1% and 8.4-28.7 &#x000b5;g/mL, respectively[<xref rid="B103" ref-type="bibr">103</xref>].</p></sec><sec><title>DIRECT MEASURES OF GLYCEMIA</title><p>Fasting and postprandial plasma glucose (FPG and PPG, respectively) are obvious measures of glycemia, providing &#x0201c;snapshot&#x0201d; glucose values for primary use in targeting treatment goals, which are currently set at ranges of 4.4-7.2 mmol/L for FPG and &#x0003c; 10.0 mmol/L for PPG[<xref rid="B1" ref-type="bibr">1</xref>]. The contributions of these measures to HbA1c have been evaluated[<xref rid="B104" ref-type="bibr">104</xref>], and significant association of PPG with cardiovascular risks was evidenced[<xref rid="B105" ref-type="bibr">105</xref>]. Daily plasma glucose values are readily available to patients who perform SMBG as a part of their regular diabetes care but reviewing and interpreting the cumulative SMBG results may propose a significant challenge for healthcare professionals[<xref rid="B106" ref-type="bibr">106</xref>].</p><p>Advances in both the analytical accuracy and software supporting SMBG, the development of continuous glucose monitoring sensors and, most recently, flash-glucose sensing technology, have prompted the development and validation of new, metrics-derived surrogate markers of glycemia which have improved our understanding of the complex glucose dynamics and have provided new tools for patients and healthcare providers in achieving optimal control of diabetes and reducing the frequency of acute and chronic complications of diabetes[<xref rid="B13" ref-type="bibr">13</xref>,<xref rid="B14" ref-type="bibr">14</xref>].</p><p>Among the integrated SMBG-derived metrics, the glycemic risk assessment diabetes equation (GRADE) and average daily risk range (ADDR) were found to best correspond with the degrees of risk of hypo- and hyperglycemia that were associated with the glucose profile[<xref rid="B107" ref-type="bibr">107</xref>], and they showed positive correlations with HbA1c and negative correlations with c-peptide levels[<xref rid="B108" ref-type="bibr">108</xref>].</p><p>As opposed to the SMBG-derived profiles, which are based on a limited number of static plasma glucose measurements throughout the day, CGMS enable a continuous insight into daily glycemia, thus enabling an individualized approach and offering a powerful tool for patients in achieving their glycemic targets and mitigating glycemic excursion. CGMS has yielded previously unreachable measures of glycemia such as average glucose exposure, time in range, hypo- and hyperglycemia and glycemic variability (glucose excursions). The glycemic variability was considered to be a significant risk factor for developing complications that was not reflected by HbA1c levels[<xref rid="B13" ref-type="bibr">13</xref>]. The advantages of using SMBG to improve patient outcomes have been amply evidenced in studies targeting various vulnerable populations of patients with diabetes such as children[<xref rid="B109" ref-type="bibr">109</xref>], pregnant women[<xref rid="B110" ref-type="bibr">110</xref>], the elderly[<xref rid="B111" ref-type="bibr">111</xref>], and the patients suffering from diabetic kidney disease[<xref rid="B112" ref-type="bibr">112</xref>] and from hypoglycemic episodes[<xref rid="B113" ref-type="bibr">113</xref>]. However, the high costs, insurance-related limitations and patient- and healthcare provider-related attitudes still hinder a wider utilization of CGMS. The recently published International Consensus on Use of Continuous Glucose Monitoring is an encouraging step forward and is aimed at providing technical and clinical recommendations on the use of CGMS in conjunction with HbA1c, and it provides a comprehensive insight into the state-of-the-art evidence supporting CGMS-derived metrics to improve patient care and clinical outcomes[<xref rid="B114" ref-type="bibr">114</xref>].</p></sec><sec><title>CONCLUSION</title><p>Hyperglycemia is a key biochemical feature of diabetes that should be rigorously controlled and maintained in a range as close to normal as possible to mitigate the risk of diabetic complications. Both the level of and exposure to hyperglycemia, as well as glycemic variability, contribute to the pathogenesis of diabetic complications, with different patterns of disease pathogenesis in patients with type 1 or type 2 diabetes. Despite its analytical and biological limitations, HbA1c remains the key biomarker of long-term glycemic control. However, it has become apparent in recent years that other glycated proteins, 1,5-AG, and integrated measures from direct glucose testing by SMBG/CGMS may provide valuable data complementary to HbA1c, particularly in circumstances when the HbA1c results may be unreliable or insufficient to assess the risk of adverse outcomes (Table <xref rid="T3" ref-type="table">3</xref>). Long-term associations of these alternative biomarkers of glycemia with the risk of diabetic complications need to be investigated to provide clinically relevant cut-off values and validate their utility in diverse populations of patients with diabetes.</p><table-wrap id="T3" position="float"><label>Table 3</label><caption><p>Characteristics of glycaemic biomarkers</p></caption><table frame="hsides" rules="groups"><thead align="center"><tr><td align="left" rowspan="1" colspan="1"><bold>Markers of hyperglycemia</bold></td><td rowspan="1" colspan="1"><bold>Assessment period</bold></td><td rowspan="1" colspan="1"><bold>Advantages</bold></td><td rowspan="1" colspan="1"><bold>Limitations</bold></td></tr></thead><tbody align="center"><tr><td align="left" rowspan="1" colspan="1">HbA1c</td><td rowspan="1" colspan="1">2-3 mo</td><td rowspan="1" colspan="1">Fasting not necessary; low interindividual variabiliy screening tool for diabetes; association with diabetes complications; standardization</td><td rowspan="1" colspan="1">Surrogate biomarker analytical interferences; biological confounders; costs</td></tr><tr><td align="left" rowspan="1" colspan="1">Fructosamine</td><td rowspan="2" colspan="1">2-3 wk</td><td rowspan="2" colspan="1">Fasting not necessary; inexpensive and easily automated; good correlation with HbA1c; association with diabetes complication; marker of choice in severe chronic kidney disease</td><td rowspan="2" colspan="1">Surrogate biomarker; higher interindividual variability; unreliable in conditions with altered protein and albumin metabolism (nephrotic disease, severe liver disease), thyroid disfunction; not standardized</td></tr><tr><td align="left" rowspan="1" colspan="1">Glycated albumin</td></tr><tr><td align="left" rowspan="1" colspan="1">1,5-anhydroglucitol</td><td rowspan="1" colspan="1">1-2 wk</td><td rowspan="1" colspan="1">Fasting not necessary; glycemic excursion detection; good correlation with HbA1c; association with diabetes complications</td><td rowspan="1" colspan="1">Surrogate biomarker; unreliable in the setting of chronic kidney disease (stage 4 and 5), dialysis, pregnancy or other conditions with changes in renal threshold (sglt inhibitors); not suitable for diabetes diagnosis</td></tr><tr><td align="left" rowspan="1" colspan="1">Fasting glucose</td><td rowspan="1" colspan="1">8-10 h</td><td rowspan="2" colspan="1">Current glycemic status; immediate availability for daily diabetes management SMBG/CGMS</td><td rowspan="2" colspan="1">Affected by acute illness and stress; SMBG and CGMS-accuracy</td></tr><tr><td align="left" rowspan="1" colspan="1">Postprandial glucose</td><td rowspan="1" colspan="1">2-4 h</td></tr><tr><td align="left" rowspan="1" colspan="1">Indices of glycaemic variabily</td><td rowspan="1" colspan="1">24-72 h</td><td rowspan="1" colspan="1">Short-term glucose dynamics; improves glycaemic control beyond HbA1c and patient&#x02019;s satisfaction/outcomes</td><td rowspan="1" colspan="1">CGMS mandatory; costs education; standardization</td></tr></tbody></table><table-wrap-foot><fn><p>HbA1c: Hemoglobin A1c; SMBG: Self-monitoring of blood glucose; CGMS: Continuous glucose monitoring system.</p></fn></table-wrap-foot></table-wrap></sec></body><back><fn-group><fn fn-type="COI-statement"><p>Conflict-of-interest statement: No potential conflicts of interest.</p></fn><fn><p>Manuscript source: Invited manuscript</p></fn><fn><p>Peer-review started: August 29, 2018</p></fn><fn><p>First decision: October 16, 2018</p></fn><fn><p>Article in press: December 5, 2018</p></fn><fn><p>Specialty type: Endocrinology and metabolism</p></fn><fn><p>Country of origin: Croatia</p></fn><fn><p>Peer-review report classification</p></fn><fn><p>Grade A (Excellent): 0</p></fn><fn><p>Grade B (Very good): B, B</p></fn><fn><p>Grade C (Good): 0</p></fn><fn><p>Grade D (Fair): 0</p></fn><fn><p>Grade E (Poor): 0</p></fn><fn><p>P- Reviewer: Ciaccio M, Khan HA S- Editor: Ma RY L- Editor: A E- Editor: Wu YXJ</p></fn></fn-group><ref-list><ref id="B1"><label>1</label><element-citation publication-type="journal"><collab>American Diabetes Association</collab><article-title>Glycemic Targets: Standards of Medical Care in Diabetes-2018</article-title><source>Diabetes Care</source><year>2018</year><volume>41</volume><fpage>S55</fpage><lpage>S64</lpage><pub-id pub-id-type="pmid">29222377</pub-id></element-citation></ref><ref id="B2"><label>2</label><element-citation publication-type="journal"><collab>Diabetes Control and Complications Trial Research Group</collab><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Genuth</surname><given-names>S</given-names></name><name><surname>Lachin</surname><given-names>J</given-names></name><name><surname>Cleary</surname><given-names>P</given-names></name><name><surname>Crofford</surname><given-names>O</given-names></name><name><surname>Davis</surname><given-names>M</given-names></name><name><surname>Rand</surname><given-names>L</given-names></name><name><surname>Siebert</surname><given-names>C</given-names></name></person-group><article-title>The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus</article-title><source>N Engl J Med</source><year>1993</year><volume>329</volume><fpage>977</fpage><lpage>986</lpage><pub-id pub-id-type="pmid">8366922</pub-id></element-citation></ref><ref id="B3"><label>3</label><element-citation publication-type="journal"><collab>Nathan DM; DCCT/EDIC Research Group</collab><article-title>The diabetes control and complications trial/epidemiology of diabetes interventions and complications study at 30 years: overview</article-title><source>Diabetes Care</source><year>2014</year><volume>37</volume><fpage>9</fpage><lpage>16</lpage><pub-id pub-id-type="pmid">24356592</pub-id></element-citation></ref><ref id="B4"><label>4</label><element-citation publication-type="journal"><collab>UK Prospective Diabetes Study (UKPDS) Group</collab><article-title>Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)</article-title><source>Lancet</source><year>1998</year><volume>352</volume><fpage>854</fpage><lpage>865</lpage><pub-id pub-id-type="pmid">9742977</pub-id></element-citation></ref><ref id="B5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Holman</surname><given-names>RR</given-names></name><name><surname>Paul</surname><given-names>SK</given-names></name><name><surname>Bethel</surname><given-names>MA</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name><name><surname>Neil</surname><given-names>HA</given-names></name></person-group><article-title>10-year follow-up of intensive glucose control in type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>359</volume><fpage>1577</fpage><lpage>1589</lpage><pub-id pub-id-type="pmid">18784090</pub-id></element-citation></ref><ref id="B6"><label>6</label><element-citation publication-type="journal"><collab>ADVANCE Collaborative Group</collab><person-group person-group-type="author"><name><surname>Patel</surname><given-names>A</given-names></name><name><surname>MacMahon</surname><given-names>S</given-names></name><name><surname>Chalmers</surname><given-names>J</given-names></name><name><surname>Neal</surname><given-names>B</given-names></name><name><surname>Billot</surname><given-names>L</given-names></name><name><surname>Woodward</surname><given-names>M</given-names></name><name><surname>Marre</surname><given-names>M</given-names></name><name><surname>Cooper</surname><given-names>M</given-names></name><name><surname>Glasziou</surname><given-names>P</given-names></name><name><surname>Grobbee</surname><given-names>D</given-names></name><name><surname>Hamet</surname><given-names>P</given-names></name><name><surname>Harrap</surname><given-names>S</given-names></name><name><surname>Heller</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Mancia</surname><given-names>G</given-names></name><name><surname>Mogensen</surname><given-names>CE</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Poulter</surname><given-names>N</given-names></name><name><surname>Rodgers</surname><given-names>A</given-names></name><name><surname>Williams</surname><given-names>B</given-names></name><name><surname>Bompoint</surname><given-names>S</given-names></name><name><surname>de Galan</surname><given-names>BE</given-names></name><name><surname>Joshi</surname><given-names>R</given-names></name><name><surname>Travert</surname><given-names>F</given-names></name></person-group><article-title>Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2560</fpage><lpage>2572</lpage><pub-id pub-id-type="pmid">18539916</pub-id></element-citation></ref><ref id="B7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Duckworth</surname><given-names>W</given-names></name><name><surname>Abraira</surname><given-names>C</given-names></name><name><surname>Moritz</surname><given-names>T</given-names></name><name><surname>Reda</surname><given-names>D</given-names></name></person-group><collab>Emanuele N, Reaven PD, Zieve FJ, Marks J, Davis SN, Hayward R, Warren SR, Goldman S, McCarren M, Vitek ME, Henderson WG, Huang GD; VADT Investigators</collab><article-title>Glucose control and vascular complications in veterans with type 2 diabetes</article-title><source>N Engl J Med</source><year>2009</year><volume>360</volume><fpage>129</fpage><lpage>139</lpage><pub-id pub-id-type="pmid">19092145</pub-id></element-citation></ref><ref id="B8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gerstein</surname><given-names>HC</given-names></name><name><surname>Miller</surname><given-names>ME</given-names></name><name><surname>Byington</surname><given-names>PR</given-names></name></person-group><collab>Goff DC Jr, Bigger JT, Buse JB, Cushman WC, Genuth S, Ismail-Beigi F, Grimm RH Jr, Probstfield JL, Simons-Morton DG, Friedewald WT</collab><article-title>Effects of intensive glucose lowering in type 2 diabetes</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2545</fpage><lpage>2559</lpage><pub-id pub-id-type="pmid">18539917</pub-id></element-citation></ref><ref id="B9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bonds</surname><given-names>DE</given-names></name><name><surname>Miller</surname><given-names>ME</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Byington</surname><given-names>RP</given-names></name><name><surname>Cutler</surname><given-names>JA</given-names></name><name><surname>Dudl</surname><given-names>RJ</given-names></name><name><surname>Ismail-Beigi</surname><given-names>F</given-names></name><name><surname>Kimel</surname><given-names>AR</given-names></name><name><surname>Hoogwerf</surname><given-names>B</given-names></name><name><surname>Horowitz</surname><given-names>KR</given-names></name><name><surname>Savage</surname><given-names>PJ</given-names></name><name><surname>Seaquist</surname><given-names>ER</given-names></name><name><surname>Simmons</surname><given-names>DL</given-names></name><name><surname>Sivitz</surname><given-names>WI</given-names></name><name><surname>Speril-Hillen</surname><given-names>JM</given-names></name><name><surname>Sweeney</surname><given-names>ME</given-names></name></person-group><article-title>The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study</article-title><source>BMJ</source><year>2010</year><volume>340</volume><fpage>b4909</fpage><pub-id pub-id-type="pmid">20061358</pub-id></element-citation></ref><ref id="B10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lenters-Westra</surname><given-names>E</given-names></name><name><surname>Schindhelm</surname><given-names>RK</given-names></name><name><surname>Bilo</surname><given-names>HJ</given-names></name><name><surname>Slingerland</surname><given-names>RJ</given-names></name></person-group><article-title>Haemoglobin A1c: Historical overview and current concepts</article-title><source>Diabetes Res Clin Pract</source><year>2013</year><volume>99</volume><fpage>75</fpage><lpage>84</lpage><pub-id pub-id-type="pmid">23176805</pub-id></element-citation></ref><ref id="B11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacks</surname><given-names>DB</given-names></name></person-group><article-title>Hemoglobin A1c in diabetes: panacea or pointless?</article-title><source>Diabetes</source><year>2013</year><volume>62</volume><fpage>41</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">23258914</pub-id></element-citation></ref><ref id="B12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>RR</given-names></name><name><surname>Rohlfing</surname><given-names>CL</given-names></name></person-group><article-title>The long and winding road to optimal HbA1c measurement</article-title><source>Clin Chim Acta</source><year>2013</year><volume>418</volume><fpage>63</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">23318564</pub-id></element-citation></ref><ref id="B13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wright</surname><given-names>LA</given-names></name><name><surname>Hirsch</surname><given-names>IB</given-names></name></person-group><article-title>Metrics Beyond Hemoglobin A1C in Diabetes Management: Time in Range, Hypoglycemia, and Other Parameters</article-title><source>Diabetes Technol Ther</source><year>2017</year><volume>19</volume><fpage>S16</fpage><lpage>S26</lpage><pub-id pub-id-type="pmid">28541136</pub-id></element-citation></ref><ref id="B14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohnert</surname><given-names>KD</given-names></name><name><surname>Heinke</surname><given-names>P</given-names></name><name><surname>Vogt</surname><given-names>L</given-names></name><name><surname>Salzsieder</surname><given-names>E</given-names></name></person-group><article-title>Utility of different glycemic control metrics for optimizing management of diabetes</article-title><source>World J Diabetes</source><year>2015</year><volume>6</volume><fpage>17</fpage><lpage>29</lpage><pub-id pub-id-type="pmid">25685275</pub-id></element-citation></ref><ref id="B15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hinzmann</surname><given-names>R</given-names></name><name><surname>Schlaeger</surname><given-names>C</given-names></name><name><surname>Tran</surname><given-names>CT</given-names></name></person-group><article-title>What do we need beyond hemoglobin A1c to get the complete picture of glycemia in people with diabetes?</article-title><source>Int J Med Sci</source><year>2012</year><volume>9</volume><fpage>665</fpage><lpage>681</lpage><pub-id pub-id-type="pmid">23055818</pub-id></element-citation></ref><ref id="B16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>RM</given-names></name><name><surname>Sacks</surname><given-names>DB</given-names></name></person-group><article-title>Comparing multiple measures of glycemia: how to transition from biomarker to diagnostic test?</article-title><source>Clin Chem</source><year>2012</year><volume>58</volume><fpage>1615</fpage><lpage>1617</lpage><pub-id pub-id-type="pmid">23115055</pub-id></element-citation></ref><ref id="B17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trivelli</surname><given-names>LA</given-names></name><name><surname>Ranney</surname><given-names>HM</given-names></name><name><surname>Lai</surname><given-names>HT</given-names></name></person-group><article-title>Hemoglobin components in patients with diabetes mellitus</article-title><source>N Engl J Med</source><year>1971</year><volume>284</volume><fpage>353</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">5539916</pub-id></element-citation></ref><ref id="B18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>John</surname><given-names>WG</given-names></name><name><surname>Lamb</surname><given-names>EJ</given-names></name></person-group><article-title>The Maillard or browning reaction in diabetes</article-title><source>Eye (Lond)</source><year>1993</year><volume>7</volume><issue>Pt 2</issue><fpage>230</fpage><lpage>237</lpage><pub-id pub-id-type="pmid">7607341</pub-id></element-citation></ref><ref id="B19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Allen</surname><given-names>DW</given-names></name><name><surname>Schroeder</surname><given-names>WA</given-names></name><name><surname>Balog</surname><given-names>J</given-names></name></person-group><article-title>Observations on the Chromatographic Heterogeneity of Normal Adult and Fetal Human Hemoglobin: A Study of the Effects of Crystallization and Chromatography on the Heterogeneity and Isoleucine Content</article-title><source>J Am Chem Soc</source><year>1958</year><volume>80</volume><fpage>1628</fpage><lpage>1634</lpage></element-citation></ref><ref id="B20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rahbar</surname><given-names>S</given-names></name></person-group><article-title>An abnormal hemoglobin in red cells of diabetics</article-title><source>Clin Chim Acta</source><year>1968</year><volume>22</volume><fpage>296</fpage><lpage>298</lpage><pub-id pub-id-type="pmid">5687098</pub-id></element-citation></ref><ref id="B21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leslie</surname><given-names>RD</given-names></name><name><surname>Pyke</surname><given-names>DA</given-names></name><name><surname>John</surname><given-names>PN</given-names></name><name><surname>White</surname><given-names>JM</given-names></name></person-group><article-title>Fast glycosylation of haemoglobin</article-title><source>Lancet</source><year>1979</year><volume>1</volume><fpage>773</fpage><lpage>774</lpage></element-citation></ref><ref id="B22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weykamp</surname><given-names>C</given-names></name></person-group><article-title>HbA1c: a review of analytical and clinical aspects</article-title><source>Ann Lab Med</source><year>2013</year><volume>33</volume><fpage>393</fpage><lpage>400</lpage><pub-id pub-id-type="pmid">24205486</pub-id></element-citation></ref><ref id="B23"><label>23</label><element-citation publication-type="journal"><collab>International Federation of Clinical Chemistry and Laboratory Medicine, IFCC Scientific Division</collab><person-group person-group-type="author"><name><surname>Mosca</surname><given-names>A</given-names></name><name><surname>Goodall</surname><given-names>I</given-names></name><name><surname>Hoshino</surname><given-names>T</given-names></name><name><surname>Jeppsson</surname><given-names>JO</given-names></name><name><surname>John</surname><given-names>WG</given-names></name><name><surname>Little</surname><given-names>RR</given-names></name><name><surname>Miedema</surname><given-names>K</given-names></name><name><surname>Myers</surname><given-names>GL</given-names></name><name><surname>Reinauer</surname><given-names>H</given-names></name><name><surname>Sacks</surname><given-names>DB</given-names></name><name><surname>Weykamp</surname><given-names>CW</given-names></name></person-group><article-title>Global standardization of glycated hemoglobin measurement: the position of the IFCC Working Group</article-title><source>Clin Chem Lab Med</source><year>2007</year><volume>45</volume><fpage>1077</fpage><lpage>1080</lpage><pub-id pub-id-type="pmid">17867998</pub-id></element-citation></ref><ref id="B24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vucic Lovrencic</surname><given-names>M</given-names></name><name><surname>Topic</surname><given-names>E</given-names></name></person-group><article-title>Hemoglobin A1c: Standardization of the "gold standard"</article-title><source>Biochem Medica</source><year>2006</year><volume>16</volume><fpage>25</fpage><lpage>36</lpage></element-citation></ref><ref id="B25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>RR</given-names></name></person-group><article-title>Glycated hemoglobin standardization--National Glycohemoglobin Standardization Program (NGSP) perspective</article-title><source>Clin Chem Lab Med</source><year>2003</year><volume>41</volume><fpage>1191</fpage><lpage>1198</lpage><pub-id pub-id-type="pmid">14598869</pub-id></element-citation></ref><ref id="B26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jeppsson</surname><given-names>JO</given-names></name><name><surname>Kobold</surname><given-names>U</given-names></name><name><surname>Barr</surname><given-names>J</given-names></name><name><surname>Finke</surname><given-names>A</given-names></name><name><surname>Hoelzel</surname><given-names>W</given-names></name><name><surname>Hoshino</surname><given-names>T</given-names></name><name><surname>Miedema</surname><given-names>K</given-names></name><name><surname>Mosca</surname><given-names>A</given-names></name><name><surname>Mauri</surname><given-names>P</given-names></name><name><surname>Paroni</surname><given-names>R</given-names></name><name><surname>Thienpont</surname><given-names>L</given-names></name><name><surname>Umemoto</surname><given-names>M</given-names></name><name><surname>Weykamp</surname><given-names>C</given-names></name></person-group><collab>International Federation of Clinical Chemistry and Laboratory Medicine (IFCC)</collab><article-title>Approved IFCC reference method for the measurement of HbA1c in human blood</article-title><source>Clin Chem Lab Med</source><year>2002</year><volume>40</volume><fpage>78</fpage><lpage>89</lpage><pub-id pub-id-type="pmid">11916276</pub-id></element-citation></ref><ref id="B27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weykamp</surname><given-names>C</given-names></name><name><surname>John</surname><given-names>WG</given-names></name><name><surname>Mosca</surname><given-names>A</given-names></name><name><surname>Hoshino</surname><given-names>T</given-names></name><name><surname>Little</surname><given-names>R</given-names></name><name><surname>Jeppsson</surname><given-names>JO</given-names></name><name><surname>Goodall</surname><given-names>I</given-names></name><name><surname>Miedema</surname><given-names>K</given-names></name><name><surname>Myers</surname><given-names>G</given-names></name><name><surname>Reinauer</surname><given-names>H</given-names></name><name><surname>Sacks</surname><given-names>DB</given-names></name><name><surname>Slingerland</surname><given-names>R</given-names></name><name><surname>Siebelder</surname><given-names>C</given-names></name></person-group><article-title>The IFCC Reference Measurement System for HbA1c: a 6-year progress report</article-title><source>Clin Chem</source><year>2008</year><volume>54</volume><fpage>240</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">18223132</pub-id></element-citation></ref><ref id="B28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanas</surname><given-names>R</given-names></name></person-group><article-title>Psychological impact of changing the scale of reported HbA(1c) results affects metabolic control</article-title><source>Diabetes Care</source><year>2002</year><volume>25</volume><fpage>2110</fpage><lpage>2111</lpage><pub-id pub-id-type="pmid">12401772</pub-id></element-citation></ref><ref id="B29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanas</surname><given-names>R</given-names></name><name><surname>John</surname><given-names>G</given-names></name></person-group><collab>International HBA1c Consensus Committee</collab><article-title>2010 consensus statement on the worldwide standardization of the hemoglobin A1C measurement</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><fpage>1903</fpage><lpage>1904</lpage><pub-id pub-id-type="pmid">20519665</pub-id></element-citation></ref><ref id="B30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hanas</surname><given-names>R</given-names></name><name><surname>John</surname><given-names>WG</given-names></name></person-group><collab>International HbA1c Consensus Committee</collab><article-title>2013 update on the worldwide standardization of the hemoglobin A(1c) measurement</article-title><source>Clin Chem Lab Med</source><year>2013</year><volume>51</volume><fpage>1041</fpage><lpage>1042</lpage><pub-id pub-id-type="pmid">23612549</pub-id></element-citation></ref><ref id="B31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacks</surname><given-names>DB</given-names></name><name><surname>Arnold</surname><given-names>M</given-names></name><name><surname>Bakris</surname><given-names>GL</given-names></name><name><surname>Bruns</surname><given-names>DE</given-names></name><name><surname>Horvath</surname><given-names>AR</given-names></name><name><surname>Kirkman</surname><given-names>MS</given-names></name><name><surname>Lernmark</surname><given-names>A</given-names></name><name><surname>Metzger</surname><given-names>BE</given-names></name><name><surname>Nathan</surname><given-names>DM</given-names></name></person-group><article-title>Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus</article-title><source>Clin Chem</source><year>2011</year><volume>57</volume><fpage>e1</fpage><lpage>e47</lpage><pub-id pub-id-type="pmid">21617152</pub-id></element-citation></ref><ref id="B32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weykamp</surname><given-names>C</given-names></name><name><surname>John</surname><given-names>G</given-names></name><name><surname>Gillery</surname><given-names>P</given-names></name><name><surname>English</surname><given-names>E</given-names></name><name><surname>Ji</surname><given-names>L</given-names></name><name><surname>Lenters-Westra</surname><given-names>E</given-names></name><name><surname>Little</surname><given-names>RR</given-names></name><name><surname>Roglic</surname><given-names>G</given-names></name><name><surname>Sacks</surname><given-names>DB</given-names></name><name><surname>Takei</surname><given-names>I</given-names></name></person-group><collab>IFCC Task Force on Implementation of HbA1c Standardization</collab><article-title>Investigation of 2 models to set and evaluate quality targets for hb a1c: biological variation and sigma-metrics</article-title><source>Clin Chem</source><year>2015</year><volume>61</volume><fpage>752</fpage><lpage>759</lpage><pub-id pub-id-type="pmid">25737535</pub-id></element-citation></ref><ref id="B33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bry</surname><given-names>L</given-names></name><name><surname>Chen</surname><given-names>PC</given-names></name><name><surname>Sacks</surname><given-names>DB</given-names></name></person-group><article-title>Effects of hemoglobin variants and chemically modified derivatives on assays for glycohemoglobin</article-title><source>Clin Chem</source><year>2001</year><volume>47</volume><fpage>153</fpage><lpage>163</lpage><pub-id pub-id-type="pmid">11159762</pub-id></element-citation></ref><ref id="B34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Little</surname><given-names>RR</given-names></name><name><surname>Rohlfing</surname><given-names>CL</given-names></name><name><surname>Tennill</surname><given-names>AL</given-names></name><name><surname>Hanson</surname><given-names>SE</given-names></name><name><surname>Connolly</surname><given-names>S</given-names></name><name><surname>Higgins</surname><given-names>T</given-names></name><name><surname>Wiedmeyer</surname><given-names>CE</given-names></name><name><surname>Weykamp</surname><given-names>CW</given-names></name><name><surname>Krause</surname><given-names>R</given-names></name><name><surname>Roberts</surname><given-names>W</given-names></name></person-group><article-title>Measurement of Hba(1C) in patients with chronic renal failure</article-title><source>Clin Chim Acta</source><year>2013</year><volume>418</volume><fpage>73</fpage><lpage>76</lpage><pub-id pub-id-type="pmid">23318566</pub-id></element-citation></ref><ref id="B35"><label>35</label><element-citation publication-type="webpage"><collab>NGSP</collab><article-title>List of NGSP Certified Methods. Accessed August 22 2018</article-title><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ngsp.org/certified.asp">http://www.ngsp.org/certified.asp</ext-link></comment></element-citation></ref><ref id="B36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Kuenen</surname><given-names>J</given-names></name><name><surname>Borg</surname><given-names>R</given-names></name><name><surname>Zheng</surname><given-names>H</given-names></name><name><surname>Schoenfeld</surname><given-names>D</given-names></name><name><surname>Heine</surname><given-names>RJ</given-names></name></person-group><collab>A1c-Derived Average Glucose Study Group</collab><article-title>Translating the A1C assay into estimated average glucose values</article-title><source>Diabetes Care</source><year>2008</year><volume>31</volume><fpage>1473</fpage><lpage>1478</lpage><pub-id pub-id-type="pmid">18540046</pub-id></element-citation></ref><ref id="B37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Pani</surname><given-names>LN</given-names></name><name><surname>Korenda</surname><given-names>L</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name><name><surname>Driver</surname><given-names>C</given-names></name><name><surname>Chamany</surname><given-names>S</given-names></name><name><surname>Fox</surname><given-names>CS</given-names></name><name><surname>Sullivan</surname><given-names>L</given-names></name><name><surname>D'Agostino</surname><given-names>RB</given-names></name><name><surname>Nathan</surname><given-names>DM</given-names></name></person-group><article-title>Effect of aging on A1C levels in individuals without diabetes: evidence from the Framingham Offspring Study and the National Health and Nutrition Examination Survey 2001-2004</article-title><source>Diabetes Care</source><year>2008</year><volume>31</volume><fpage>1991</fpage><lpage>1996</lpage><pub-id pub-id-type="pmid">18628569</pub-id></element-citation></ref><ref id="B38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cavagnolli</surname><given-names>G</given-names></name><name><surname>Pimentel</surname><given-names>AL</given-names></name><name><surname>Freitas</surname><given-names>PA</given-names></name><name><surname>Gross</surname><given-names>JL</given-names></name><name><surname>Camargo</surname><given-names>JL</given-names></name></person-group><article-title>Effect of ethnicity on HbA1c levels in individuals without diabetes: Systematic review and meta-analysis</article-title><source>PLoS One</source><year>2017</year><volume>12</volume><fpage>e0171315</fpage><pub-id pub-id-type="pmid">28192447</pub-id></element-citation></ref><ref id="B39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leong</surname><given-names>A</given-names></name><name><surname>Wheeler</surname><given-names>E</given-names></name></person-group><article-title>Genetics of HbA1c: a case study in clinical translation</article-title><source>Curr Opin Genet Dev</source><year>2018</year><volume>50</volume><fpage>79</fpage><lpage>85</lpage><pub-id pub-id-type="pmid">29522974</pub-id></element-citation></ref><ref id="B40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wheeler</surname><given-names>E</given-names></name><name><surname>Leong</surname><given-names>A</given-names></name><name><surname>Liu</surname><given-names>CT</given-names></name><name><surname>Hivert</surname><given-names>MF</given-names></name><name><surname>Strawbridge</surname><given-names>RJ</given-names></name><name><surname>Podmore</surname><given-names>C</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Yao</surname><given-names>J</given-names></name><name><surname>Sim</surname><given-names>X</given-names></name><name><surname>Hong</surname><given-names>J</given-names></name><name><surname>Chu</surname><given-names>AY</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Wang</surname><given-names>X</given-names></name><name><surname>Chen</surname><given-names>P</given-names></name><name><surname>Maruthur</surname><given-names>NM</given-names></name><name><surname>Porneala</surname><given-names>BC</given-names></name><name><surname>Sharp</surname><given-names>SJ</given-names></name><name><surname>Jia</surname><given-names>Y</given-names></name><name><surname>Kabagambe</surname><given-names>EK</given-names></name><name><surname>Chang</surname><given-names>LC</given-names></name><name><surname>Chen</surname><given-names>WM</given-names></name><name><surname>Elks</surname><given-names>CE</given-names></name><name><surname>Evans</surname><given-names>DS</given-names></name><name><surname>Fan</surname><given-names>Q</given-names></name><name><surname>Giulianini</surname><given-names>F</given-names></name><name><surname>Go</surname><given-names>MJ</given-names></name><name><surname>Hottenga</surname><given-names>JJ</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Jackson</surname><given-names>AU</given-names></name><name><surname>Kanoni</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>YJ</given-names></name><name><surname>Kleber</surname><given-names>ME</given-names></name><name><surname>Ladenvall</surname><given-names>C</given-names></name><name><surname>Lecoeur</surname><given-names>C</given-names></name><name><surname>Lim</surname><given-names>SH</given-names></name><name><surname>Lu</surname><given-names>Y</given-names></name><name><surname>Mahajan</surname><given-names>A</given-names></name><name><surname>Marzi</surname><given-names>C</given-names></name><name><surname>Nalls</surname><given-names>MA</given-names></name><name><surname>Navarro</surname><given-names>P</given-names></name><name><surname>Nolte</surname><given-names>IM</given-names></name><name><surname>Rose</surname><given-names>LM</given-names></name><name><surname>Rybin</surname><given-names>DV</given-names></name><name><surname>Sanna</surname><given-names>S</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Stram</surname><given-names>DO</given-names></name><name><surname>Takeuchi</surname><given-names>F</given-names></name><name><surname>Tan</surname><given-names>SP</given-names></name><name><surname>van der Most</surname><given-names>PJ</given-names></name><name><surname>Van Vliet-Ostaptchouk</surname><given-names>JV</given-names></name><name><surname>Wong</surname><given-names>A</given-names></name><name><surname>Yengo</surname><given-names>L</given-names></name><name><surname>Zhao</surname><given-names>W</given-names></name><name><surname>Goel</surname><given-names>A</given-names></name><name><surname>Martinez Larrad</surname><given-names>MT</given-names></name><name><surname>Radke</surname><given-names>D</given-names></name><name><surname>Salo</surname><given-names>P</given-names></name><name><surname>Tanaka</surname><given-names>T</given-names></name><name><surname>van Iperen</surname><given-names>EPA</given-names></name><name><surname>Abecasis</surname><given-names>G</given-names></name><name><surname>Afaq</surname><given-names>S</given-names></name><name><surname>Alizadeh</surname><given-names>BZ</given-names></name><name><surname>Bertoni</surname><given-names>AG</given-names></name><name><surname>Bonnefond</surname><given-names>A</given-names></name><name><surname>B&#x000f6;ttcher</surname><given-names>Y</given-names></name><name><surname>Bottinger</surname><given-names>EP</given-names></name><name><surname>Campbell</surname><given-names>H</given-names></name><name><surname>Carlson</surname><given-names>OD</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Cho</surname><given-names>YS</given-names></name><name><surname>Garvey</surname><given-names>WT</given-names></name><name><surname>Gieger</surname><given-names>C</given-names></name><name><surname>Goodarzi</surname><given-names>MO</given-names></name><name><surname>Grallert</surname><given-names>H</given-names></name><name><surname>Hamsten</surname><given-names>A</given-names></name><name><surname>Hartman</surname><given-names>CA</given-names></name><name><surname>Herder</surname><given-names>C</given-names></name><name><surname>Hsiung</surname><given-names>CA</given-names></name><name><surname>Huang</surname><given-names>J</given-names></name><name><surname>Igase</surname><given-names>M</given-names></name><name><surname>Isono</surname><given-names>M</given-names></name><name><surname>Katsuya</surname><given-names>T</given-names></name><name><surname>Khor</surname><given-names>CC</given-names></name><name><surname>Kiess</surname><given-names>W</given-names></name><name><surname>Kohara</surname><given-names>K</given-names></name><name><surname>Kovacs</surname><given-names>P</given-names></name><name><surname>Lee</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>WJ</given-names></name><name><surname>Lehne</surname><given-names>B</given-names></name><name><surname>Li</surname><given-names>H</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Lobbens</surname><given-names>S</given-names></name><name><surname>Luan</surname><given-names>J</given-names></name><name><surname>Lyssenko</surname><given-names>V</given-names></name><name><surname>Meitinger</surname><given-names>T</given-names></name><name><surname>Miki</surname><given-names>T</given-names></name><name><surname>Miljkovic</surname><given-names>I</given-names></name><name><surname>Moon</surname><given-names>S</given-names></name><name><surname>Mulas</surname><given-names>A</given-names></name><name><surname>M&#x000fc;ller</surname><given-names>G</given-names></name><name><surname>M&#x000fc;ller-Nurasyid</surname><given-names>M</given-names></name><name><surname>Nagaraja</surname><given-names>R</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Pankow</surname><given-names>JS</given-names></name><name><surname>Polasek</surname><given-names>O</given-names></name><name><surname>Prokopenko</surname><given-names>I</given-names></name><name><surname>Ramos</surname><given-names>PS</given-names></name><name><surname>Rasmussen-Torvik</surname><given-names>L</given-names></name><name><surname>Rathmann</surname><given-names>W</given-names></name><name><surname>Rich</surname><given-names>SS</given-names></name><name><surname>Robertson</surname><given-names>NR</given-names></name><name><surname>Roden</surname><given-names>M</given-names></name><name><surname>Roussel</surname><given-names>R</given-names></name><name><surname>Rudan</surname><given-names>I</given-names></name><name><surname>Scott</surname><given-names>RA</given-names></name><name><surname>Scott</surname><given-names>WR</given-names></name><name><surname>Sennblad</surname><given-names>B</given-names></name><name><surname>Siscovick</surname><given-names>DS</given-names></name><name><surname>Strauch</surname><given-names>K</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Swertz</surname><given-names>M</given-names></name><name><surname>Tajuddin</surname><given-names>SM</given-names></name><name><surname>Taylor</surname><given-names>KD</given-names></name><name><surname>Teo</surname><given-names>YY</given-names></name><name><surname>Tham</surname><given-names>YC</given-names></name><name><surname>T&#x000f6;njes</surname><given-names>A</given-names></name><name><surname>Wareham</surname><given-names>NJ</given-names></name><name><surname>Willemsen</surname><given-names>G</given-names></name><name><surname>Wilsgaard</surname><given-names>T</given-names></name><name><surname>Hingorani</surname><given-names>AD</given-names></name><name><surname>Egan</surname><given-names>J</given-names></name><name><surname>Ferrucci</surname><given-names>L</given-names></name><name><surname>Hovingh</surname><given-names>GK</given-names></name><name><surname>Jula</surname><given-names>A</given-names></name><name><surname>Kivimaki</surname><given-names>M</given-names></name><name><surname>Kumari</surname><given-names>M</given-names></name><name><surname>Nj&#x000f8;lstad</surname><given-names>I</given-names></name><name><surname>Palmer</surname><given-names>CNA</given-names></name><name><surname>Serrano R&#x000ed;os</surname><given-names>M</given-names></name><name><surname>Stumvoll</surname><given-names>M</given-names></name><name><surname>Watkins</surname><given-names>H</given-names></name><name><surname>Aung</surname><given-names>T</given-names></name><name><surname>Bl&#x000fc;her</surname><given-names>M</given-names></name><name><surname>Boehnke</surname><given-names>M</given-names></name><name><surname>Boomsma</surname><given-names>DI</given-names></name><name><surname>Bornstein</surname><given-names>SR</given-names></name><name><surname>Chambers</surname><given-names>JC</given-names></name><name><surname>Chasman</surname><given-names>DI</given-names></name><name><surname>Chen</surname><given-names>YI</given-names></name><name><surname>Chen</surname><given-names>YT</given-names></name><name><surname>Cheng</surname><given-names>CY</given-names></name><name><surname>Cucca</surname><given-names>F</given-names></name><name><surname>de Geus</surname><given-names>EJC</given-names></name><name><surname>Deloukas</surname><given-names>P</given-names></name><name><surname>Evans</surname><given-names>MK</given-names></name><name><surname>Fornage</surname><given-names>M</given-names></name><name><surname>Friedlander</surname><given-names>Y</given-names></name><name><surname>Froguel</surname><given-names>P</given-names></name><name><surname>Groop</surname><given-names>L</given-names></name><name><surname>Gross</surname><given-names>MD</given-names></name><name><surname>Harris</surname><given-names>TB</given-names></name><name><surname>Hayward</surname><given-names>C</given-names></name><name><surname>Heng</surname><given-names>CK</given-names></name><name><surname>Ingelsson</surname><given-names>E</given-names></name><name><surname>Kato</surname><given-names>N</given-names></name><name><surname>Kim</surname><given-names>BJ</given-names></name><name><surname>Koh</surname><given-names>WP</given-names></name><name><surname>Kooner</surname><given-names>JS</given-names></name><name><surname>K&#x000f6;rner</surname><given-names>A</given-names></name><name><surname>Kuh</surname><given-names>D</given-names></name><name><surname>Kuusisto</surname><given-names>J</given-names></name><name><surname>Laakso</surname><given-names>M</given-names></name><name><surname>Lin</surname><given-names>X</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Loos</surname><given-names>RJF</given-names></name><name><surname>Magnusson</surname><given-names>PKE</given-names></name><name><surname>M&#x000e4;rz</surname><given-names>W</given-names></name><name><surname>McCarthy</surname><given-names>MI</given-names></name><name><surname>Oldehinkel</surname><given-names>AJ</given-names></name><name><surname>Ong</surname><given-names>KK</given-names></name><name><surname>Pedersen</surname><given-names>NL</given-names></name><name><surname>Pereira</surname><given-names>MA</given-names></name><name><surname>Peters</surname><given-names>A</given-names></name><name><surname>Ridker</surname><given-names>PM</given-names></name><name><surname>Sabanayagam</surname><given-names>C</given-names></name><name><surname>Sale</surname><given-names>M</given-names></name><name><surname>Saleheen</surname><given-names>D</given-names></name><name><surname>Saltevo</surname><given-names>J</given-names></name><name><surname>Schwarz</surname><given-names>PE</given-names></name><name><surname>Sheu</surname><given-names>WHH</given-names></name><name><surname>Snieder</surname><given-names>H</given-names></name><name><surname>Spector</surname><given-names>TD</given-names></name><name><surname>Tabara</surname><given-names>Y</given-names></name><name><surname>Tuomilehto</surname><given-names>J</given-names></name><name><surname>van Dam</surname><given-names>RM</given-names></name><name><surname>Wilson</surname><given-names>JG</given-names></name><name><surname>Wilson</surname><given-names>JF</given-names></name><name><surname>Wolffenbuttel</surname><given-names>BHR</given-names></name><name><surname>Wong</surname><given-names>TY</given-names></name><name><surname>Wu</surname><given-names>JY</given-names></name><name><surname>Yuan</surname><given-names>JM</given-names></name><name><surname>Zonderman</surname><given-names>AB</given-names></name><name><surname>Soranzo</surname><given-names>N</given-names></name><name><surname>Guo</surname><given-names>X</given-names></name><name><surname>Roberts</surname><given-names>DJ</given-names></name><name><surname>Florez</surname><given-names>JC</given-names></name><name><surname>Sladek</surname><given-names>R</given-names></name><name><surname>Dupuis</surname><given-names>J</given-names></name><name><surname>Morris</surname><given-names>AP</given-names></name><name><surname>Tai</surname><given-names>ES</given-names></name><name><surname>Selvin</surname><given-names>E</given-names></name><name><surname>Rotter</surname><given-names>JI</given-names></name><name><surname>Langenberg</surname><given-names>C</given-names></name><name><surname>Barroso</surname><given-names>I</given-names></name><name><surname>Meigs</surname><given-names>JB</given-names></name></person-group><collab>EPIC-CVD Consortium; EPIC-InterAct Consortium; Lifelines Cohort Study</collab><article-title>Impact of common genetic determinants of Hemoglobin A1c on type 2 diabetes risk and diagnosis in ancestrally diverse populations: A transethnic genome-wide meta-analysis</article-title><source>PLoS Med</source><year>2017</year><volume>14</volume><fpage>e1002383</fpage><pub-id pub-id-type="pmid">28898252</pub-id></element-citation></ref><ref id="B41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>English</surname><given-names>E</given-names></name><name><surname>Idris</surname><given-names>I</given-names></name><name><surname>Smith</surname><given-names>G</given-names></name><name><surname>Dhatariya</surname><given-names>K</given-names></name><name><surname>Kilpatrick</surname><given-names>ES</given-names></name><name><surname>John</surname><given-names>WG</given-names></name></person-group><article-title>The effect of anaemia and abnormalities of erythrocyte indices on HbA1c analysis: a systematic review</article-title><source>Diabetologia</source><year>2015</year><volume>58</volume><fpage>1409</fpage><lpage>1421</lpage><pub-id pub-id-type="pmid">25994072</pub-id></element-citation></ref><ref id="B42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Malka</surname><given-names>R</given-names></name><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Higgins</surname><given-names>JM</given-names></name></person-group><article-title>Mechanistic modeling of hemoglobin glycation and red blood cell kinetics enables personalized diabetes monitoring</article-title><source>Sci Transl Med</source><year>2016</year><volume>8</volume><fpage>359ra130</fpage></element-citation></ref><ref id="B43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>RM</given-names></name><name><surname>Holmes</surname><given-names>YR</given-names></name><name><surname>Chenier</surname><given-names>TC</given-names></name><name><surname>Joiner</surname><given-names>CH</given-names></name></person-group><article-title>Discordance between HbA1c and fructosamine: evidence for a glycosylation gap and its relation to diabetic nephropathy</article-title><source>Diabetes Care</source><year>2003</year><volume>26</volume><fpage>163</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">12502674</pub-id></element-citation></ref><ref id="B44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>RM</given-names></name><name><surname>Lindsell</surname><given-names>CJ</given-names></name></person-group><article-title>When the blood glucose and the HbA(1c) don't match: turning uncertainty into opportunity</article-title><source>Diabetes Care</source><year>2012</year><volume>35</volume><fpage>2421</fpage><lpage>2423</lpage><pub-id pub-id-type="pmid">23173128</pub-id></element-citation></ref><ref id="B45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cohen</surname><given-names>RM</given-names></name><name><surname>Snieder</surname><given-names>H</given-names></name><name><surname>Lindsell</surname><given-names>CJ</given-names></name><name><surname>Beyan</surname><given-names>H</given-names></name><name><surname>Hawa</surname><given-names>MI</given-names></name><name><surname>Blinko</surname><given-names>S</given-names></name><name><surname>Edwards</surname><given-names>R</given-names></name><name><surname>Spector</surname><given-names>TD</given-names></name><name><surname>Leslie</surname><given-names>RD</given-names></name></person-group><article-title>Evidence for independent heritability of the glycation gap (glycosylation gap) fraction of HbA1c in nondiabetic twins</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>1739</fpage><lpage>1743</lpage><pub-id pub-id-type="pmid">16873773</pub-id></element-citation></ref><ref id="B46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sacks</surname><given-names>DB</given-names></name><name><surname>Nathan</surname><given-names>DM</given-names></name><name><surname>Lachin</surname><given-names>JM</given-names></name></person-group><article-title>Gaps in the glycation gap hypothesis</article-title><source>Clin Chem</source><year>2011</year><volume>57</volume><fpage>150</fpage><lpage>152</lpage><pub-id pub-id-type="pmid">21127149</pub-id></element-citation></ref><ref id="B47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chalew</surname><given-names>SA</given-names></name><name><surname>McCarter</surname><given-names>RJ</given-names></name><name><surname>Thomas</surname><given-names>J</given-names></name><name><surname>Thomson</surname><given-names>JL</given-names></name><name><surname>Hempe</surname><given-names>JM</given-names></name></person-group><article-title>A comparison of the Glycosylation Gap and Hemoglobin Glycation Index in patients with diabetes</article-title><source>J Diabetes Complications</source><year>2005</year><volume>19</volume><fpage>218</fpage><lpage>222</lpage><pub-id pub-id-type="pmid">15993356</pub-id></element-citation></ref><ref id="B48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nayak</surname><given-names>AU</given-names></name><name><surname>Nevill</surname><given-names>AM</given-names></name><name><surname>Bassett</surname><given-names>P</given-names></name><name><surname>Singh</surname><given-names>BM</given-names></name></person-group><article-title>Association of glycation gap with mortality and vascular complications in diabetes</article-title><source>Diabetes Care</source><year>2013</year><volume>36</volume><fpage>3247</fpage><lpage>3253</lpage><pub-id pub-id-type="pmid">23835697</pub-id></element-citation></ref><ref id="B49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hempe</surname><given-names>JM</given-names></name><name><surname>Liu</surname><given-names>S</given-names></name><name><surname>Myers</surname><given-names>L</given-names></name><name><surname>McCarter</surname><given-names>RJ</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Fonseca</surname><given-names>V</given-names></name></person-group><article-title>The hemoglobin glycation index identifies subpopulations with harms or benefits from intensive treatment in the ACCORD trial</article-title><source>Diabetes Care</source><year>2015</year><volume>38</volume><fpage>1067</fpage><lpage>1074</lpage><pub-id pub-id-type="pmid">25887355</pub-id></element-citation></ref><ref id="B50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khera</surname><given-names>PK</given-names></name><name><surname>Joiner</surname><given-names>CH</given-names></name><name><surname>Carruthers</surname><given-names>A</given-names></name><name><surname>Lindsell</surname><given-names>CJ</given-names></name><name><surname>Smith</surname><given-names>EP</given-names></name><name><surname>Franco</surname><given-names>RS</given-names></name><name><surname>Holmes</surname><given-names>YR</given-names></name><name><surname>Cohen</surname><given-names>RM</given-names></name></person-group><article-title>Evidence for interindividual heterogeneity in the glucose gradient across the human red blood cell membrane and its relationship to hemoglobin glycation</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>2445</fpage><lpage>2452</lpage><pub-id pub-id-type="pmid">18591386</pub-id></element-citation></ref><ref id="B51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dunmore</surname><given-names>SJ</given-names></name><name><surname>Al-Derawi</surname><given-names>AS</given-names></name><name><surname>Nayak</surname><given-names>AU</given-names></name><name><surname>Narshi</surname><given-names>A</given-names></name><name><surname>Nevill</surname><given-names>AM</given-names></name><name><surname>Hellwig</surname><given-names>A</given-names></name><name><surname>Majebi</surname><given-names>A</given-names></name><name><surname>Kirkham</surname><given-names>P</given-names></name><name><surname>Brown</surname><given-names>JE</given-names></name><name><surname>Singh</surname><given-names>BM</given-names></name></person-group><article-title>Evidence That Differences in Fructosamine-3-Kinase Activity May Be Associated With the Glycation Gap in Human Diabetes</article-title><source>Diabetes</source><year>2018</year><volume>67</volume><fpage>131</fpage><lpage>136</lpage><pub-id pub-id-type="pmid">29066600</pub-id></element-citation></ref><ref id="B52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Inzucchi</surname><given-names>SE</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Diamant</surname><given-names>M</given-names></name><name><surname>Ferrannini</surname><given-names>E</given-names></name><name><surname>Nauck</surname><given-names>M</given-names></name><name><surname>Peters</surname><given-names>AL</given-names></name><name><surname>Tsapas</surname><given-names>A</given-names></name><name><surname>Wender</surname><given-names>R</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name></person-group><article-title>Management of hyperglycemia in type 2 diabetes, 2015: a patient-centered approach: update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes</article-title><source>Diabetes Care</source><year>2015</year><volume>38</volume><fpage>140</fpage><lpage>149</lpage><pub-id pub-id-type="pmid">25538310</pub-id></element-citation></ref><ref id="B53"><label>53</label><element-citation publication-type="journal"><collab>American Diabetes Association</collab><article-title>2. Classification and Diagnosis of Diabetes: <italic>Standards of Medical Care in Diabetes-2018</italic></article-title><source>Diabetes Care</source><year>2018</year><volume>41</volume><fpage>S13</fpage><lpage>S27</lpage><pub-id pub-id-type="pmid">29222373</pub-id></element-citation></ref><ref id="B54"><label>54</label><element-citation publication-type="webpage"><collab>World Health Organisation</collab><article-title>Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus Abbreviated Report of a WHO Consultation</article-title><comment>Available from: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/">http://www.who.int/diabetes/publications/diagnosis_diabetes2011/en/</ext-link></comment></element-citation></ref><ref id="B55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sherwani</surname><given-names>SI</given-names></name><name><surname>Khan</surname><given-names>HA</given-names></name><name><surname>Ekhzaimy</surname><given-names>A</given-names></name><name><surname>Masood</surname><given-names>A</given-names></name><name><surname>Sakharkar</surname><given-names>MK</given-names></name></person-group><article-title>Significance of HbA1c Test in Diagnosis and Prognosis of Diabetic Patients</article-title><source>Biomark Insights</source><year>2016</year><volume>11</volume><fpage>95</fpage><lpage>104</lpage><pub-id pub-id-type="pmid">27398023</pub-id></element-citation></ref><ref id="B56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cowie</surname><given-names>CC</given-names></name><name><surname>Rust</surname><given-names>KF</given-names></name><name><surname>Byrd-Holt</surname><given-names>DD</given-names></name><name><surname>Gregg</surname><given-names>EW</given-names></name><name><surname>Ford</surname><given-names>ES</given-names></name><name><surname>Geiss</surname><given-names>LS</given-names></name><name><surname>Bainbridge</surname><given-names>KE</given-names></name><name><surname>Fradkin</surname><given-names>JE</given-names></name></person-group><article-title>Prevalence of diabetes and high risk for diabetes using A1C criteria in the U.S. population in 1988-2006</article-title><source>Diabetes Care</source><year>2010</year><volume>33</volume><fpage>562</fpage><lpage>568</lpage><pub-id pub-id-type="pmid">20067953</pub-id></element-citation></ref><ref id="B57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Davidson</surname><given-names>MB</given-names></name><name><surname>Pan</surname><given-names>D</given-names></name></person-group><article-title>Epidemiological ramifications of diagnosing diabetes with HbA1c levels</article-title><source>J Diabetes Complications</source><year>2014</year><volume>28</volume><fpage>464</fpage><lpage>469</lpage><pub-id pub-id-type="pmid">24768273</pub-id></element-citation></ref><ref id="B58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nowicka</surname><given-names>P</given-names></name><name><surname>Santoro</surname><given-names>N</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Lartaud</surname><given-names>D</given-names></name><name><surname>Shaw</surname><given-names>MM</given-names></name><name><surname>Goldberg</surname><given-names>R</given-names></name><name><surname>Guandalini</surname><given-names>C</given-names></name><name><surname>Savoye</surname><given-names>M</given-names></name><name><surname>Rose</surname><given-names>P</given-names></name><name><surname>Caprio</surname><given-names>S</given-names></name></person-group><article-title>Utility of hemoglobin A(1c) for diagnosing prediabetes and diabetes in obese children and adolescents</article-title><source>Diabetes Care</source><year>2011</year><volume>34</volume><fpage>1306</fpage><lpage>1311</lpage><pub-id pub-id-type="pmid">21515842</pub-id></element-citation></ref><ref id="B59"><label>59</label><element-citation publication-type="journal"><collab>NCD Risk Factor Collaboration (NCD-RisC)</collab><article-title>Effects of diabetes definition on global surveillance of diabetes prevalence and diagnosis: a pooled analysis of 96 population-based studies with 331,288 participants</article-title><source>Lancet Diabetes Endocrinol</source><year>2015</year><volume>3</volume><fpage>624</fpage><lpage>637</lpage><pub-id pub-id-type="pmid">26109024</pub-id></element-citation></ref><ref id="B60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Church</surname><given-names>D</given-names></name><name><surname>Simmons</surname><given-names>D</given-names></name></person-group><article-title>More evidence of the problems of using HbA1c for diagnosing diabetes? The known knowns, the known unknowns and the unknown unknowns</article-title><source>J Intern Med</source><year>2014</year><volume>276</volume><fpage>171</fpage><lpage>173</lpage><pub-id pub-id-type="pmid">24443985</pub-id></element-citation></ref><ref id="B61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armbruster</surname><given-names>DA</given-names></name></person-group><article-title>Fructosamine: structure, analysis, and clinical usefulness</article-title><source>Clin Chem</source><year>1987</year><volume>33</volume><fpage>2153</fpage><lpage>2163</lpage><pub-id pub-id-type="pmid">3319287</pub-id></element-citation></ref><ref id="B62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Parrinello</surname><given-names>CM</given-names></name><name><surname>Selvin</surname><given-names>E</given-names></name></person-group><article-title>Beyond HbA1c and glucose: the role of nontraditional glycemic markers in diabetes diagnosis, prognosis, and management</article-title><source>Curr Diab Rep</source><year>2014</year><volume>14</volume><fpage>548</fpage><pub-id pub-id-type="pmid">25249070</pub-id></element-citation></ref><ref id="B63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JE</given-names></name><name><surname>Lee</surname><given-names>JW</given-names></name><name><surname>Fujii</surname><given-names>T</given-names></name><name><surname>Fujii</surname><given-names>N</given-names></name><name><surname>Choi</surname><given-names>JW</given-names></name></person-group><article-title>The ratio of estimated average glucose to fasting plasma glucose level is superior to glycated albumin, hemoglobin A1c, fructosamine, and GA/A1c ratio for assessing &#x003b2;-cell function in childhood diabetes</article-title><source>Biomed Res Int</source><year>2014</year><volume>2014</volume><fpage>370790</fpage><pub-id pub-id-type="pmid">25013775</pub-id></element-citation></ref><ref id="B64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danese</surname><given-names>E</given-names></name><name><surname>Montagnana</surname><given-names>M</given-names></name><name><surname>Nouvenne</surname><given-names>A</given-names></name><name><surname>Lippi</surname><given-names>G</given-names></name></person-group><article-title>Advantages and pitfalls of fructosamine and glycated albumin in the diagnosis and treatment of diabetes</article-title><source>J Diabetes Sci Technol</source><year>2015</year><volume>9</volume><fpage>169</fpage><lpage>176</lpage><pub-id pub-id-type="pmid">25591856</pub-id></element-citation></ref><ref id="B65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Silver</surname><given-names>AC</given-names></name><name><surname>Lamb</surname><given-names>E</given-names></name><name><surname>Cattell</surname><given-names>WR</given-names></name><name><surname>Dawnay</surname><given-names>AB</given-names></name></person-group><article-title>Investigation and validation of the affinity chromatography method for measuring glycated albumin in serum and urine</article-title><source>Clin Chim Acta</source><year>1991</year><volume>202</volume><fpage>11</fpage><lpage>22</lpage><pub-id pub-id-type="pmid">1807865</pub-id></element-citation></ref><ref id="B66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Day</surname><given-names>JF</given-names></name><name><surname>Thorpe</surname><given-names>SR</given-names></name><name><surname>Baynes</surname><given-names>JW</given-names></name></person-group><article-title>Nonenzymatically glucosylated albumin. In vitro preparation and isolation from normal human serum</article-title><source>J Biol Chem</source><year>1979</year><volume>254</volume><fpage>595</fpage><lpage>597</lpage><pub-id pub-id-type="pmid">762083</pub-id></element-citation></ref><ref id="B67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yasukawa</surname><given-names>K</given-names></name><name><surname>Abe</surname><given-names>F</given-names></name><name><surname>Shida</surname><given-names>N</given-names></name><name><surname>Koizumi</surname><given-names>Y</given-names></name><name><surname>Uchida</surname><given-names>T</given-names></name><name><surname>Noguchi</surname><given-names>K</given-names></name><name><surname>Shima</surname><given-names>K</given-names></name></person-group><article-title>High-performance affinity chromatography system for the rapid, efficient assay of glycated albumin</article-title><source>J Chromatogr</source><year>1992</year><volume>597</volume><fpage>271</fpage><lpage>275</lpage><pub-id pub-id-type="pmid">1517327</pub-id></element-citation></ref><ref id="B68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brede</surname><given-names>C</given-names></name><name><surname>Hop</surname><given-names>B</given-names></name><name><surname>J&#x000f8;rgensen</surname><given-names>K</given-names></name><name><surname>Skadberg</surname><given-names>&#x000d8;</given-names></name></person-group><article-title>Measurement of glycated albumin in serum and plasma by LC-MS/MS</article-title><source>Scand J Clin Lab Invest</source><year>2016</year><volume>76</volume><fpage>195</fpage><lpage>201</lpage><pub-id pub-id-type="pmid">26898156</pub-id></element-citation></ref><ref id="B69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Testa</surname><given-names>R</given-names></name><name><surname>Guerra</surname><given-names>E</given-names></name><name><surname>Bonfigli</surname><given-names>AR</given-names></name><name><surname>Di Gaetano</surname><given-names>N</given-names></name><name><surname>Santini</surname><given-names>G</given-names></name><name><surname>Ceriotti</surname><given-names>F</given-names></name></person-group><article-title>Analytical Performances of an Enzymatic Assay for the Measurement of Glycated Albumin</article-title><source>J Appl Lab Med</source><year>2016</year><volume>1</volume><fpage>162</fpage><lpage>171</lpage></element-citation></ref><ref id="B70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kouzuma</surname><given-names>T</given-names></name><name><surname>Usami</surname><given-names>T</given-names></name><name><surname>Yamakoshi</surname><given-names>M</given-names></name><name><surname>Takahashi</surname><given-names>M</given-names></name><name><surname>Imamura</surname><given-names>S</given-names></name></person-group><article-title>An enzymatic method for the measurement of glycated albumin in biological samples</article-title><source>Clin Chim Acta</source><year>2002</year><volume>324</volume><fpage>61</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">12204426</pub-id></element-citation></ref><ref id="B71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kohzuma</surname><given-names>T</given-names></name><name><surname>Koga</surname><given-names>M</given-names></name></person-group><article-title>Lucica GA-L glycated albumin assay kit: a new diagnostic test for diabetes mellitus</article-title><source>Mol Diagn Ther</source><year>2010</year><volume>14</volume><fpage>49</fpage><lpage>51</lpage><pub-id pub-id-type="pmid">20121290</pub-id></element-citation></ref><ref id="B72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abidin</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>L</given-names></name><name><surname>Dou</surname><given-names>C</given-names></name><name><surname>Datta</surname><given-names>A</given-names></name><name><surname>Yuan</surname><given-names>C</given-names></name></person-group><article-title>An improved enzymatic assay for glycated serum protein</article-title><source>Anal Methods</source><year>2013</year><volume>5</volume><fpage>2461</fpage><lpage>2469</lpage></element-citation></ref><ref id="B73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cefalu</surname><given-names>WT</given-names></name><name><surname>Bell-Farrow</surname><given-names>AD</given-names></name><name><surname>Petty</surname><given-names>M</given-names></name><name><surname>Izlar</surname><given-names>C</given-names></name><name><surname>Smith</surname><given-names>JA</given-names></name></person-group><article-title>Clinical validation of a second-generation fructosamine assay</article-title><source>Clin Chem</source><year>1991</year><volume>37</volume><fpage>1252</fpage><lpage>1256</lpage><pub-id pub-id-type="pmid">1855298</pub-id></element-citation></ref><ref id="B74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Goldstein</surname><given-names>DE</given-names></name><name><surname>Little</surname><given-names>RR</given-names></name><name><surname>Lorenz</surname><given-names>RA</given-names></name><name><surname>Malone</surname><given-names>JI</given-names></name><name><surname>Nathan</surname><given-names>D</given-names></name><name><surname>Peterson</surname><given-names>CM</given-names></name><name><surname>Sacks</surname><given-names>DB</given-names></name></person-group><article-title>Tests of glycemia in diabetes</article-title><source>Diabetes Care</source><year>2004</year><volume>27</volume><fpage>1761</fpage><lpage>1773</lpage><pub-id pub-id-type="pmid">15220264</pub-id></element-citation></ref><ref id="B75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rodr&#x000ed;guez-Segade</surname><given-names>S</given-names></name><name><surname>Rodr&#x000ed;guez</surname><given-names>J</given-names></name><name><surname>Cami&#x000f1;a</surname><given-names>F</given-names></name></person-group><article-title>Corrected Fructosamine improves both correlation with HbA<sub>1C</sub> and diagnostic performance</article-title><source>Clin Biochem</source><year>2017</year><volume>50</volume><fpage>110</fpage><lpage>115</lpage><pub-id pub-id-type="pmid">27777100</pub-id></element-citation></ref><ref id="B76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agarwal</surname><given-names>MM</given-names></name><name><surname>Hughes</surname><given-names>PF</given-names></name><name><surname>Punnose</surname><given-names>J</given-names></name><name><surname>Ezimokhai</surname><given-names>M</given-names></name><name><surname>Thomas</surname><given-names>L</given-names></name></person-group><article-title>Gestational diabetes screening of a multiethnic, high-risk population using glycated proteins</article-title><source>Diabetes Res Clin Pract</source><year>2001</year><volume>51</volume><fpage>67</fpage><lpage>73</lpage><pub-id pub-id-type="pmid">11137184</pub-id></element-citation></ref><ref id="B77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Takahashi</surname><given-names>S</given-names></name><name><surname>Uchino</surname><given-names>H</given-names></name><name><surname>Shimizu</surname><given-names>T</given-names></name><name><surname>Kanazawa</surname><given-names>A</given-names></name><name><surname>Tamura</surname><given-names>Y</given-names></name><name><surname>Sakai</surname><given-names>K</given-names></name><name><surname>Watada</surname><given-names>H</given-names></name><name><surname>Hirose</surname><given-names>T</given-names></name><name><surname>Kawamori</surname><given-names>R</given-names></name><name><surname>Tanaka</surname><given-names>Y</given-names></name></person-group><article-title>Comparison of glycated albumin (GA) and glycated hemoglobin (HbA1c) in type 2 diabetic patients: usefulness of GA for evaluation of short-term changes in glycemic control</article-title><source>Endocr J</source><year>2007</year><volume>54</volume><fpage>139</fpage><lpage>144</lpage><pub-id pub-id-type="pmid">17159300</pub-id></element-citation></ref><ref id="B78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rondeau</surname><given-names>P</given-names></name><name><surname>Bourdon</surname><given-names>E</given-names></name></person-group><article-title>The glycation of albumin: structural and functional impacts</article-title><source>Biochimie</source><year>2011</year><volume>93</volume><fpage>645</fpage><lpage>658</lpage><pub-id pub-id-type="pmid">21167901</pub-id></element-citation></ref><ref id="B79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lu</surname><given-names>JM</given-names></name><name><surname>Ji</surname><given-names>LN</given-names></name><name><surname>Li</surname><given-names>YF</given-names></name><name><surname>Li</surname><given-names>QM</given-names></name><name><surname>Lin</surname><given-names>SS</given-names></name><name><surname>Lv</surname><given-names>XF</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Xu</surname><given-names>Y</given-names></name><name><surname>Guo</surname><given-names>XH</given-names></name><name><surname>Guo</surname><given-names>QY</given-names></name><name><surname>Ma</surname><given-names>L</given-names></name><name><surname>Du</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>YL</given-names></name><name><surname>Zhao</surname><given-names>CL</given-names></name><name><surname>Zhang</surname><given-names>QL</given-names></name><name><surname>She</surname><given-names>QM</given-names></name><name><surname>Jiao</surname><given-names>XM</given-names></name><name><surname>Lu</surname><given-names>MH</given-names></name><name><surname>Pan</surname><given-names>RQ</given-names></name><name><surname>Gao</surname><given-names>Y</given-names></name></person-group><article-title>Glycated albumin is superior to glycated hemoglobin for glycemic control assessment at an early stage of diabetes treatment: A multicenter, prospective study</article-title><source>J Diabetes Complications</source><year>2016</year><volume>30</volume><fpage>1609</fpage><lpage>1613</lpage><pub-id pub-id-type="pmid">27496253</pub-id></element-citation></ref><ref id="B80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vos</surname><given-names>FE</given-names></name><name><surname>Schollum</surname><given-names>JB</given-names></name><name><surname>Coulter</surname><given-names>CV</given-names></name><name><surname>Manning</surname><given-names>PJ</given-names></name><name><surname>Duffull</surname><given-names>SB</given-names></name><name><surname>Walker</surname><given-names>RJ</given-names></name></person-group><article-title>Assessment of markers of glycaemic control in diabetic patients with chronic kidney disease using continuous glucose monitoring</article-title><source>Nephrology (Carlton)</source><year>2012</year><volume>17</volume><fpage>182</fpage><lpage>188</lpage><pub-id pub-id-type="pmid">21883672</pub-id></element-citation></ref><ref id="B81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dozio</surname><given-names>E</given-names></name><name><surname>Corradi</surname><given-names>V</given-names></name><name><surname>Proglio</surname><given-names>M</given-names></name><name><surname>Vianello</surname><given-names>E</given-names></name><name><surname>Menicanti</surname><given-names>L</given-names></name><name><surname>Rigolini</surname><given-names>R</given-names></name><name><surname>Caprara</surname><given-names>C</given-names></name><name><surname>de Cal</surname><given-names>M</given-names></name><name><surname>Corsi Romanelli</surname><given-names>MM</given-names></name><name><surname>Ronco</surname><given-names>C</given-names></name></person-group><article-title>Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)</article-title><source>Diabetes Res Clin Pract</source><year>2018</year><volume>140</volume><fpage>9</fpage><lpage>17</lpage><pub-id pub-id-type="pmid">29596954</pub-id></element-citation></ref><ref id="B82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvin</surname><given-names>E</given-names></name><name><surname>Sacks</surname><given-names>DB</given-names></name></person-group><article-title>Monitoring Glycemic Control in End-Stage Renal Disease: What Should Be Measured?</article-title><source>Clin Chem</source><year>2017</year><volume>63</volume><fpage>447</fpage><lpage>449</lpage><pub-id pub-id-type="pmid">27974388</pub-id></element-citation></ref><ref id="B83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Araki</surname><given-names>T</given-names></name><name><surname>Ishikawa</surname><given-names>Y</given-names></name><name><surname>Okazaki</surname><given-names>H</given-names></name><name><surname>Tani</surname><given-names>Y</given-names></name><name><surname>Toyooka</surname><given-names>S</given-names></name><name><surname>Satake</surname><given-names>M</given-names></name><name><surname>Miwa</surname><given-names>U</given-names></name><name><surname>Tadokoro</surname><given-names>K</given-names></name></person-group><collab>Japanese Red Cross GA Research Group</collab><article-title>Introduction of glycated albumin measurement for all blood donors and the prevalence of a high glycated albumin level in Japan</article-title><source>J Diabetes Investig</source><year>2012</year><volume>3</volume><fpage>492</fpage><lpage>497</lpage></element-citation></ref><ref id="B84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loomis</surname><given-names>SJ</given-names></name><name><surname>Li</surname><given-names>M</given-names></name><name><surname>Maruthur</surname><given-names>NM</given-names></name><name><surname>Baldridge</surname><given-names>AS</given-names></name><name><surname>North</surname><given-names>KE</given-names></name><name><surname>Mei</surname><given-names>H</given-names></name><name><surname>Morrison</surname><given-names>A</given-names></name><name><surname>Carson</surname><given-names>AP</given-names></name><name><surname>Pankow</surname><given-names>JS</given-names></name><name><surname>Boerwinkle</surname><given-names>E</given-names></name><name><surname>Scharpf</surname><given-names>R</given-names></name><name><surname>Rasmussen-Torvik</surname><given-names>LJ</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name><name><surname>Duggal</surname><given-names>P</given-names></name><name><surname>K&#x000f6;ttgen</surname><given-names>A</given-names></name><name><surname>Selvin</surname><given-names>E</given-names></name></person-group><article-title>Genome-Wide Association Study of Serum Fructosamine and Glycated Albumin in Adults Without Diagnosed Diabetes: Results From the Atherosclerosis Risk in Communities Study</article-title><source>Diabetes</source><year>2018</year><volume>67</volume><fpage>1684</fpage><lpage>1696</lpage><pub-id pub-id-type="pmid">29844224</pub-id></element-citation></ref><ref id="B85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvin</surname><given-names>E</given-names></name><name><surname>Rawlings</surname><given-names>AM</given-names></name><name><surname>Grams</surname><given-names>M</given-names></name><name><surname>Klein</surname><given-names>R</given-names></name><name><surname>Sharrett</surname><given-names>AR</given-names></name><name><surname>Steffes</surname><given-names>M</given-names></name><name><surname>Coresh</surname><given-names>J</given-names></name></person-group><article-title>Fructosamine and glycated albumin for risk stratification and prediction of incident diabetes and microvascular complications: a prospective cohort analysis of the Atherosclerosis Risk in Communities (ARIC) study</article-title><source>Lancet Diabetes Endocrinol</source><year>2014</year><volume>2</volume><fpage>279</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">24703046</pub-id></element-citation></ref><ref id="B86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Juraschek</surname><given-names>SP</given-names></name><name><surname>Steffes</surname><given-names>MW</given-names></name><name><surname>Selvin</surname><given-names>E</given-names></name></person-group><article-title>Associations of alternative markers of glycemia with hemoglobin A(1c) and fasting glucose</article-title><source>Clin Chem</source><year>2012</year><volume>58</volume><fpage>1648</fpage><lpage>1655</lpage><pub-id pub-id-type="pmid">23019309</pub-id></element-citation></ref><ref id="B87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bellia</surname><given-names>C</given-names></name><name><surname>Zaninotto</surname><given-names>M</given-names></name><name><surname>Cosma</surname><given-names>C</given-names></name><name><surname>Agnello</surname><given-names>L</given-names></name><name><surname>Bivona</surname><given-names>G</given-names></name><name><surname>Marinova</surname><given-names>M</given-names></name><name><surname>Lo Sasso</surname><given-names>B</given-names></name><name><surname>Plebani</surname><given-names>M</given-names></name><name><surname>Ciaccio</surname><given-names>M</given-names></name></person-group><article-title>Clinical usefulness of Glycated Albumin in the diagnosis of diabetes: Results from an Italian study</article-title><source>Clin Biochem</source><year>2018</year><volume>54</volume><fpage>68</fpage><lpage>72</lpage><pub-id pub-id-type="pmid">29486186</pub-id></element-citation></ref><ref id="B88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yamanouchi</surname><given-names>T</given-names></name><name><surname>Tachibana</surname><given-names>Y</given-names></name><name><surname>Akanuma</surname><given-names>H</given-names></name><name><surname>Minoda</surname><given-names>S</given-names></name><name><surname>Shinohara</surname><given-names>T</given-names></name><name><surname>Moromizato</surname><given-names>H</given-names></name><name><surname>Miyashita</surname><given-names>H</given-names></name><name><surname>Akaoka</surname><given-names>I</given-names></name></person-group><article-title>Origin and disposal of 1,5-anhydroglucitol, a major polyol in the human body</article-title><source>Am J Physiol</source><year>1992</year><volume>263</volume><fpage>E268</fpage><lpage>E273</lpage><pub-id pub-id-type="pmid">1514606</pub-id></element-citation></ref><ref id="B89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nerby</surname><given-names>CL</given-names></name><name><surname>Stickle</surname><given-names>DF</given-names></name></person-group><article-title>1,5-anhydroglucitol monitoring in diabetes: a mass balance perspective</article-title><source>Clin Biochem</source><year>2009</year><volume>42</volume><fpage>158</fpage><lpage>167</lpage><pub-id pub-id-type="pmid">18804100</pub-id></element-citation></ref><ref id="B90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tazawa</surname><given-names>S</given-names></name><name><surname>Yamato</surname><given-names>T</given-names></name><name><surname>Fujikura</surname><given-names>H</given-names></name><name><surname>Hiratochi</surname><given-names>M</given-names></name><name><surname>Itoh</surname><given-names>F</given-names></name><name><surname>Tomae</surname><given-names>M</given-names></name><name><surname>Takemura</surname><given-names>Y</given-names></name><name><surname>Maruyama</surname><given-names>H</given-names></name><name><surname>Sugiyama</surname><given-names>T</given-names></name><name><surname>Wakamatsu</surname><given-names>A</given-names></name><name><surname>Isogai</surname><given-names>T</given-names></name><name><surname>Isaji</surname><given-names>M</given-names></name></person-group><article-title>SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose</article-title><source>Life Sci</source><year>2005</year><volume>76</volume><fpage>1039</fpage><lpage>1050</lpage><pub-id pub-id-type="pmid">15607332</pub-id></element-citation></ref><ref id="B91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Akanuma</surname><given-names>Y</given-names></name><name><surname>Morita</surname><given-names>M</given-names></name><name><surname>Fukuzawa</surname><given-names>N</given-names></name><name><surname>Yamanouchi</surname><given-names>T</given-names></name><name><surname>Akanuma</surname><given-names>H</given-names></name></person-group><article-title>Urinary excretion of 1,5-anhydro-D-glucitol accompanying glucose excretion in diabetic patients</article-title><source>Diabetologia</source><year>1988</year><volume>31</volume><fpage>831</fpage><lpage>835</lpage><pub-id pub-id-type="pmid">3234638</pub-id></element-citation></ref><ref id="B92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dungan</surname><given-names>KM</given-names></name><name><surname>Buse</surname><given-names>JB</given-names></name><name><surname>Largay</surname><given-names>J</given-names></name><name><surname>Kelly</surname><given-names>MM</given-names></name><name><surname>Button</surname><given-names>EA</given-names></name><name><surname>Kato</surname><given-names>S</given-names></name><name><surname>Wittlin</surname><given-names>S</given-names></name></person-group><article-title>1,5-anhydroglucitol and postprandial hyperglycemia as measured by continuous glucose monitoring system in moderately controlled patients with diabetes</article-title><source>Diabetes Care</source><year>2006</year><volume>29</volume><fpage>1214</fpage><lpage>1219</lpage><pub-id pub-id-type="pmid">16731998</pub-id></element-citation></ref><ref id="B93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kishimoto</surname><given-names>M</given-names></name><name><surname>Yamasaki</surname><given-names>Y</given-names></name><name><surname>Kubota</surname><given-names>M</given-names></name><name><surname>Arai</surname><given-names>K</given-names></name><name><surname>Morishima</surname><given-names>T</given-names></name><name><surname>Kawamori</surname><given-names>R</given-names></name><name><surname>Kamada</surname><given-names>T</given-names></name></person-group><article-title>1,5-Anhydro-D-glucitol evaluates daily glycemic excursions in well-controlled NIDDM</article-title><source>Diabetes Care</source><year>1995</year><volume>18</volume><fpage>1156</fpage><lpage>1159</lpage><pub-id pub-id-type="pmid">7587851</pub-id></element-citation></ref><ref id="B94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dungan</surname><given-names>KM</given-names></name></person-group><article-title>1,5-anhydroglucitol (GlycoMark) as a marker of short-term glycemic control and glycemic excursions</article-title><source>Expert Rev Mol Diagn</source><year>2008</year><volume>8</volume><fpage>9</fpage><lpage>19</lpage><pub-id pub-id-type="pmid">18088226</pub-id></element-citation></ref><ref id="B95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Januszewski</surname><given-names>AS</given-names></name><name><surname>Karschimkus</surname><given-names>C</given-names></name><name><surname>Davis</surname><given-names>KE</given-names></name><name><surname>O'Neal</surname><given-names>D</given-names></name><name><surname>Ward</surname><given-names>G</given-names></name><name><surname>Jenkins</surname><given-names>AJ</given-names></name></person-group><article-title>Plasma 1,5 anhydroglucitol levels, a measure of short-term glycaemia: assay assessment and lower levels in diabetic vs. non-diabetic subjects</article-title><source>Diabetes Res Clin Pract</source><year>2012</year><volume>95</volume><fpage>e17</fpage><lpage>e19</lpage><pub-id pub-id-type="pmid">22024285</pub-id></element-citation></ref><ref id="B96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Stettler</surname><given-names>C</given-names></name><name><surname>Stahl</surname><given-names>M</given-names></name><name><surname>Allemann</surname><given-names>S</given-names></name><name><surname>Diem</surname><given-names>P</given-names></name><name><surname>Schmidlin</surname><given-names>K</given-names></name><name><surname>Zwahlen</surname><given-names>M</given-names></name><name><surname>Riesen</surname><given-names>W</given-names></name><name><surname>Keller</surname><given-names>U</given-names></name><name><surname>Christ</surname><given-names>E</given-names></name></person-group><article-title>Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients</article-title><source>Diabetes Care</source><year>2008</year><volume>31</volume><fpage>1534</fpage><lpage>1535</lpage><pub-id pub-id-type="pmid">18426859</pub-id></element-citation></ref><ref id="B97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Monnier</surname><given-names>L</given-names></name><name><surname>Colette</surname><given-names>C</given-names></name><name><surname>Dunseath</surname><given-names>GJ</given-names></name><name><surname>Owens</surname><given-names>DR</given-names></name></person-group><article-title>The loss of postprandial glycemic control precedes stepwise deterioration of fasting with worsening diabetes</article-title><source>Diabetes Care</source><year>2007</year><volume>30</volume><fpage>263</fpage><lpage>269</lpage><pub-id pub-id-type="pmid">17259492</pub-id></element-citation></ref><ref id="B98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvin</surname><given-names>E</given-names></name><name><surname>Rynders</surname><given-names>GP</given-names></name><name><surname>Steffes</surname><given-names>MW</given-names></name></person-group><article-title>Comparison of two assays for serum 1,5-anhydroglucitol</article-title><source>Clin Chim Acta</source><year>2011</year><volume>412</volume><fpage>793</fpage><lpage>795</lpage><pub-id pub-id-type="pmid">21238440</pub-id></element-citation></ref><ref id="B99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x00105;browska</surname><given-names>AM</given-names></name><name><surname>Tarach</surname><given-names>JS</given-names></name><name><surname>Kurowska</surname><given-names>M</given-names></name></person-group><article-title>1,5-Anhydroglucitol (1,5-Ag) and its Usefulness in Clinical Practice</article-title><source>Medical And Biological Sciences</source><year>2012</year><volume>26</volume><fpage>11</fpage><lpage>17</lpage></element-citation></ref><ref id="B100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Onorato</surname><given-names>JM</given-names></name><name><surname>Langish</surname><given-names>RA</given-names></name><name><surname>Shipkova</surname><given-names>PA</given-names></name><name><surname>Sanders</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Kwagh</surname><given-names>J</given-names></name><name><surname>Dutta</surname><given-names>S</given-names></name></person-group><article-title>A novel method for the determination of 1,5-anhydroglucitol, a glycemic marker, in human urine utilizing hydrophilic interaction liquid chromatography/MS(3)</article-title><source>J Chromatogr B Analyt Technol Biomed Life Sci</source><year>2008</year><volume>873</volume><fpage>144</fpage><lpage>150</lpage></element-citation></ref><ref id="B101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lawler</surname><given-names>PR</given-names></name><name><surname>Mora</surname><given-names>S</given-names></name></person-group><article-title>Moving beyond mean glycemia: 1,5-anhydroglucitol and microvascular complications of diabetes</article-title><source>Clin Chem</source><year>2014</year><volume>60</volume><fpage>1359</fpage><lpage>1361</lpage><pub-id pub-id-type="pmid">25217368</pub-id></element-citation></ref><ref id="B102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>WJ</given-names></name><name><surname>Park</surname><given-names>CY</given-names></name><name><surname>Lee</surname><given-names>KB</given-names></name><name><surname>Park</surname><given-names>SE</given-names></name><name><surname>Rhee</surname><given-names>EJ</given-names></name><name><surname>Lee</surname><given-names>WY</given-names></name><name><surname>Oh</surname><given-names>KW</given-names></name><name><surname>Park</surname><given-names>SW</given-names></name></person-group><article-title>Serum 1,5-anhydroglucitol concentrations are a reliable index of glycemic control in type 2 diabetes with mild or moderate renal dysfunction</article-title><source>Diabetes Care</source><year>2012</year><volume>35</volume><fpage>281</fpage><lpage>286</lpage><pub-id pub-id-type="pmid">22210564</pub-id></element-citation></ref><ref id="B103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Selvin</surname><given-names>E</given-names></name><name><surname>Warren</surname><given-names>B</given-names></name><name><surname>He</surname><given-names>X</given-names></name><name><surname>Sacks</surname><given-names>DB</given-names></name><name><surname>Saenger</surname><given-names>AK</given-names></name></person-group><article-title>Establishment of Community-Based Reference Intervals for Fructosamine, Glycated Albumin, and 1,5-Anhydroglucitol</article-title><source>Clin Chem</source><year>2018</year><volume>64</volume><fpage>843</fpage><lpage>850</lpage><pub-id pub-id-type="pmid">29436378</pub-id></element-citation></ref><ref id="B104"><label>104</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riddle</surname><given-names>M</given-names></name><name><surname>Umpierrez</surname><given-names>G</given-names></name><name><surname>DiGenio</surname><given-names>A</given-names></name><name><surname>Zhou</surname><given-names>R</given-names></name><name><surname>Rosenstock</surname><given-names>J</given-names></name></person-group><article-title>Contributions of basal and postprandial hyperglycemia over a wide range of A1C levels before and after treatment intensification in type 2 diabetes</article-title><source>Diabetes Care</source><year>2011</year><volume>34</volume><fpage>2508</fpage><lpage>2514</lpage><pub-id pub-id-type="pmid">22028279</pub-id></element-citation></ref><ref id="B105"><label>105</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raz</surname><given-names>I</given-names></name><name><surname>Wilson</surname><given-names>PW</given-names></name><name><surname>Strojek</surname><given-names>K</given-names></name><name><surname>Kowalska</surname><given-names>I</given-names></name><name><surname>Bozikov</surname><given-names>V</given-names></name><name><surname>Gitt</surname><given-names>AK</given-names></name><name><surname>Jermendy</surname><given-names>G</given-names></name><name><surname>Campaigne</surname><given-names>BN</given-names></name><name><surname>Kerr</surname><given-names>L</given-names></name><name><surname>Milicevic</surname><given-names>Z</given-names></name><name><surname>Jacober</surname><given-names>SJ</given-names></name></person-group><article-title>Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial</article-title><source>Diabetes Care</source><year>2009</year><volume>32</volume><fpage>381</fpage><lpage>386</lpage><pub-id pub-id-type="pmid">19246588</pub-id></element-citation></ref><ref id="B106"><label>106</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kovatchev</surname><given-names>BP</given-names></name></person-group><article-title>Metrics for glycaemic control - from HbA<sub>1c</sub> to continuous glucose monitoring</article-title><source>Nat Rev Endocrinol</source><year>2017</year><volume>13</volume><fpage>425</fpage><lpage>436</lpage><pub-id pub-id-type="pmid">28304392</pub-id></element-citation></ref><ref id="B107"><label>107</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>NR</given-names></name><name><surname>Hindmarsh</surname><given-names>PC</given-names></name><name><surname>Stevens</surname><given-names>RJ</given-names></name><name><surname>Stratton</surname><given-names>IM</given-names></name><name><surname>Levy</surname><given-names>JC</given-names></name><name><surname>Matthews</surname><given-names>DR</given-names></name></person-group><article-title>A method for assessing quality of control from glucose profiles</article-title><source>Diabet Med</source><year>2007</year><volume>24</volume><fpage>753</fpage><lpage>758</lpage><pub-id pub-id-type="pmid">17459094</pub-id></element-citation></ref><ref id="B108"><label>108</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>SK</given-names></name><name><surname>Kwon</surname><given-names>SB</given-names></name><name><surname>Yoon</surname><given-names>KH</given-names></name><name><surname>Ahn</surname><given-names>KJ</given-names></name><name><surname>Kang</surname><given-names>JG</given-names></name><name><surname>Jung</surname><given-names>HS</given-names></name><name><surname>Kang</surname><given-names>ES</given-names></name><name><surname>Kim</surname><given-names>JH</given-names></name><name><surname>Kim</surname><given-names>KW</given-names></name></person-group><article-title>Assessment of glycemic lability and severity of hypoglycemia in Korean patients with type 1 diabetes</article-title><source>Endocr J</source><year>2011</year><volume>58</volume><fpage>433</fpage><lpage>440</lpage><pub-id pub-id-type="pmid">21505268</pub-id></element-citation></ref><ref id="B109"><label>109</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lal</surname><given-names>RA</given-names></name><name><surname>Maahs</surname><given-names>DM</given-names></name></person-group><article-title>Clinical Use of Continuous Glucose Monitoring in Pediatrics</article-title><source>Diabetes Technol Ther</source><year>2017</year><volume>19</volume><fpage>S37</fpage><lpage>S43</lpage><pub-id pub-id-type="pmid">28541138</pub-id></element-citation></ref><ref id="B110"><label>110</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Feig</surname><given-names>DS</given-names></name><name><surname>Donovan</surname><given-names>LE</given-names></name><name><surname>Corcoy</surname><given-names>R</given-names></name><name><surname>Murphy</surname><given-names>KE</given-names></name><name><surname>Amiel</surname><given-names>SA</given-names></name><name><surname>Hunt</surname><given-names>KF</given-names></name><name><surname>Asztalos</surname><given-names>E</given-names></name><name><surname>Barrett</surname><given-names>JFR</given-names></name><name><surname>Sanchez</surname><given-names>JJ</given-names></name><name><surname>de Leiva</surname><given-names>A</given-names></name><name><surname>Hod</surname><given-names>M</given-names></name><name><surname>Jovanovic</surname><given-names>L</given-names></name><name><surname>Keely</surname><given-names>E</given-names></name><name><surname>McManus</surname><given-names>R</given-names></name><name><surname>Hutton</surname><given-names>EK</given-names></name><name><surname>Meek</surname><given-names>CL</given-names></name><name><surname>Stewart</surname><given-names>ZA</given-names></name><name><surname>Wysocki</surname><given-names>T</given-names></name><name><surname>O'Brien</surname><given-names>R</given-names></name><name><surname>Ruedy</surname><given-names>K</given-names></name><name><surname>Kollman</surname><given-names>C</given-names></name><name><surname>Tomlinson</surname><given-names>G</given-names></name><name><surname>Murphy</surname><given-names>HR</given-names></name></person-group><collab>CONCEPTT Collaborative Group</collab><article-title>Continuous glucose monitoring in pregnant women with type 1 diabetes (CONCEPTT): a multicentre international randomised controlled trial</article-title><source>Lancet</source><year>2017</year><volume>390</volume><fpage>2347</fpage><lpage>2359</lpage><pub-id pub-id-type="pmid">28923465</pub-id></element-citation></ref><ref id="B111"><label>111</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ruedy</surname><given-names>KJ</given-names></name><name><surname>Parkin</surname><given-names>CG</given-names></name><name><surname>Riddlesworth</surname><given-names>TD</given-names></name><name><surname>Graham</surname><given-names>C</given-names></name></person-group><collab>DIAMOND Study Group</collab><article-title>Continuous Glucose Monitoring in Older Adults With Type 1 and Type 2 Diabetes Using Multiple Daily Injections of Insulin: Results From the DIAMOND Trial</article-title><source>J Diabetes Sci Technol</source><year>2017</year><volume>11</volume><fpage>1138</fpage><lpage>1146</lpage><pub-id pub-id-type="pmid">28449590</pub-id></element-citation></ref><ref id="B112"><label>112</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yeoh</surname><given-names>E</given-names></name><name><surname>Lim</surname><given-names>BK</given-names></name><name><surname>Fun</surname><given-names>S</given-names></name><name><surname>Tong</surname><given-names>J</given-names></name><name><surname>Yeoh</surname><given-names>LY</given-names></name><name><surname>Sum</surname><given-names>CF</given-names></name><name><surname>Subramaniam</surname><given-names>T</given-names></name><name><surname>Lim</surname><given-names>SC</given-names></name></person-group><article-title>Efficacy of self-monitoring of blood glucose versus retrospective continuous glucose monitoring in improving glycaemic control in diabetic kidney disease patients</article-title><source>Nephrology (Carlton)</source><year>2018</year><volume>23</volume><fpage>264</fpage><lpage>268</lpage><pub-id pub-id-type="pmid">27933715</pub-id></element-citation></ref><ref id="B113"><label>113</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adolfsson</surname><given-names>P</given-names></name><name><surname>Rentoul</surname><given-names>D</given-names></name><name><surname>Klinkenbijl</surname><given-names>B</given-names></name><name><surname>Parkin</surname><given-names>CG</given-names></name></person-group><article-title>Hypoglycaemia Remains the Key Obstacle to Optimal Glycaemic Control - Continuous Glucose Monitoring is the Solution</article-title><source>Eur Endocrinol</source><year>2018</year><volume>14</volume><fpage>50</fpage><lpage>56</lpage><pub-id pub-id-type="pmid">30349594</pub-id></element-citation></ref><ref id="B114"><label>114</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Danne</surname><given-names>t</given-names></name><name><surname>Nimri</surname><given-names>r</given-names></name><name><surname>Battelino</surname><given-names>T</given-names></name><name><surname>Bergenstal</surname><given-names>RM</given-names></name><name><surname>Close</surname><given-names>KL</given-names></name><name><surname>DeVries</surname><given-names>JH</given-names></name><name><surname>Garg</surname><given-names>S</given-names></name><name><surname>Heinemann</surname><given-names>L</given-names></name><name><surname>Hirsch</surname><given-names>I</given-names></name><name><surname>Amiel</surname><given-names>SA</given-names></name><name><surname>Beck</surname><given-names>R</given-names></name><name><surname>Bosi</surname><given-names>E</given-names></name><name><surname>Buckingham</surname><given-names>B</given-names></name><name><surname>Cobelli</surname><given-names>C</given-names></name><name><surname>Dassau</surname><given-names>E</given-names></name><name><surname>Doyle</surname><given-names>FJ 3rd</given-names></name></person-group><collab>Heller S, Hovorka R, Jia W, Jones T, Kordonouri O, Kovatchev B, Kowalski A, Laffel L, Maahs D, Murphy HR, N&#x000f8;rgaard K, Parkin CG, Renard E, Saboo B, Scharf M, Tamborlane WV, Weinzimer SA, Phillip M</collab><article-title>International Consensus on Use of Continuous Glucose Monitoring</article-title><source>Diabetes Care</source><year>2017</year><volume>40</volume><fpage>1631</fpage><lpage>1640</lpage><pub-id pub-id-type="pmid">29162583</pub-id></element-citation></ref></ref-list></back></article>